分類: ACN Newswire

SINGAPORE, Mar 16, 2026 - (ACN Newswire via SeaPRwire.com) - In a world where living costs continue to rise, making your money work harder for you is a necessity. While a standard savings account offers a base interest rate, a bonus savings account allows you to earn higher interest by meeting specific conditions.By understanding the mechanics of these accounts, you can turn your idle cash into a productive asset. This article explores the features of these accounts and how they can help you reach your financial goals sooner.What is a Bonus Savings Account?A bonus savings account is a type of bank account that rewards you with higher interest rates when you meet specific conditions. Unlike a basic account that pays a flat, low rate regardless of your activity, these accounts are designed to encourage healthy financial habits.Generally, your total interest is split into two parts: base interest and bonus interest. The base interest is what you earn on every dollar, regardless of your activity. The bonus interest is an additional percentage added when you fulfil certain requirements, such as increasing your monthly balance or spending on a linked credit card.How a Bonus Savings Account Helps You Earn MoreThe primary appeal of a bonus savings account is the ability to earn interest rates that are often several times higher than standard savings accounts. Here is how they help you maximise your earnings:1. Rewarding Consistent Savers: Many accounts reward you for not spending your money. For example, some accounts offer bonus interest if your monthly average balance increases compared to the previous month. This encourages you to keep your funds in the account rather than withdrawing them for impulsive purchases, allowing compounding to work in your favour.2. Consolidating Your Financial Activities: Banks often use a bonus savings account to reward loyalty. You might earn extra interest by linking your salary credit or meeting a minimum spend on the bank's credit cards. By centring your financial activities around one account, you can unlock higher tiers of interest than with a basic savings plan.3. Tiered Interest Structures: Most bonus accounts use a tiered system. This means that as your balance grows, the interest rate on specific brackets of your funds increases. This structure is particularly beneficial for those with growing savings, as it allows larger balances to earn higher rates.Common Requirements to Unlock Bonus InterestTo make the most of a bonus savings account, you need to understand the typical requirements. Banks in Singapore usually look for the following:Balance Growth: Maintaining or increasing your balance month on month.Salary Credit: Having your monthly take-home pay credited directly into the account via your employer.Spend Requirements: Using a linked debit or credit card for a minimum amount (often SGD 500) each month.Investing or Insuring: Purchasing eligible insurance or investment products through the bank.Is a Bonus Savings Account Right for You?While the high interest rates are attractive, a bonus savings account is most effective when it aligns with your natural spending and saving habits.If you are someone who saves a portion of your income every month and rarely withdraws from your reserves, an account that rewards balance growth is an excellent fit. However, if you prefer an account that doesn't require you to track credit card spending or investment tiers, you may want to consider a simpler savings account.Strategies to Maximise Your InterestTo ensure you never miss out on your bonus interest, consider these simple steps:Automate Your Savings: Set up a standing instruction to move a fixed amount into your bonus savings account every month. This ensures your balance grows consistently without you having to remember to do it manually.Track Your Monthly Average Balance: Be mindful of the mid-month balance rather than just the balance on the last day of the month. Large withdrawals in the middle of the month may lower your average balance.Consolidate Spending: If your account requires a minimum card spend, try to put all your essential costs, such as groceries, transport, and utilities, on that specific card to hit the target easily.Final ThoughtsA bonus savings account can be a useful tool for improving returns on your cash savings. It transforms the act of saving from a passive habit into a rewarding strategy. By choosing an account that fits your lifestyle and staying disciplined with the requirements, you can help your hard-earned money grow at a higher rate.Disclaimer: This article is for general information only and does not have any regard to the specific investment objectives, financial situation and particular needs of any specific person. The views expressed in this article are solely those of the author. This article shall not be regarded as an offer, recommendation, solicitation or advice. You may wish to consult your own professional advisers about this article, in particular, a financial professional before making financial decisions. Any past events, trends and/or performance referred to in this article may not necessarily be indicative of future events, trends or performance. This article is based on certain assumptions and reflects prevailing conditions as at the time of publication, which are subject to change at any time without notice. The author and publisher of this article as well as any other parties associated with this article make no representation or warranty of any kind, whether express, implied or statutory, in respect of this article and accept no liability or responsibility for the completeness or accuracy of this article or any error, inaccuracy or omission relating to this article and/or any consequence, injury, loss or damage howsoever suffered by any person relating to this article, in particular, arising from any reliance by any person on this article. Publishers or platforms may be compensated for access to third party websites.Contact Information:Name : Sonakshi MurzeEmail : Sonakshi.murze@iquanti.comJob Title : ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月16日 - (亞太商訊 via SeaPRwire.com) - 中國利郎有限公司（「中國利郎」或「公司」，及其附屬公司，統稱「集團」；股份編號：1234）今天公佈其二零二五年全年業績。中國利郎主席兼非執行董事王冬星先生說：「二零二五年，中國內地服裝行業在宏觀經濟穩步復甦與消費市場溫和增長的背景下，整體保持基本穩定、承壓前行的發展態勢。男裝市場在消費升級大趨勢下呈現結構性分化，商務休閒、輕商務等中高端細分賽道成為增長核心動力，行業正加速從『數量競爭』邁向以『創新、品質與可持續發展』為核心的高質量競爭階段。中國利郎以差異化品牌矩陣深耕男裝市場，通過『利郎 LILANZ』主系列、『利郎 LESS IS MORE』輕商務系列及『萬星威 MUNSINGWEAR』運動線構建多元業務佈局，全方位滿足市場高品質、多元化的消費需求。同時，集團優化全渠道營銷佈局，強化線上線下協同營運，線上積極拓展新興平台、線下加速推動DTC模式，同步推進國際化佈局，多維度提升品牌影響力與營運效能。」年內，集團收入同比增長11.5%至人民幣40.7億元。其中，輕商務及其他系列收入大幅上升28.4%，主要得益於單店平均銷售額的大幅提升以及新零售渠道的突出表現。主系列收入增長6.0%，主要由於集團自去年起從分銷商收回分銷權轉以DTC模式經營後，於年內初步產生經營效益。毛利率為49.6%，同比上升1.9個百分點，主要因為直營銷售佔比上升提高平均單價，加上因收回分銷權產生的一次性收入扣除有所減少所致。權益股東應佔利潤為人民幣5.0億元（二零二四年：人民幣4.6億元），同比上升9.0%。股東應佔利潤率為12.3%，同比下降0.3個百分點。每股盈利同比上升9.0%至人民幣41.96分。董事會建議派發末期股息每股13港仙（二零二四年：9港仙）及特別末期股息每股3港仙（二零二四年：3港仙），連同已派發的中期股息，全年每股派息合共32港仙，維持穩定的派息比率。集團於年內以差異化品牌矩陣為核心戰略，深耕男裝市場。「利郎 LILANZ」主系列持續鞏固傳統男裝市場的競爭壁壘，透過優化產品結構、深化區域渠道佈局與滲透，進一步提升品牌在核心市場的認知度與市場份額。繼去年完成東北地區及江蘇省的分銷權回購轉制後，集團於年內加速推進渠道革新，再完成收回山東省及重慶市一級分銷商的經營權。針對年輕消費者的「利郎 LESS IS MORE」輕商務系列繼續以全直營模式經營，開店策略集中在消費者偏好的購物中心，以精準的門店形象提升消費體驗。截至二零二五年十二月底，主系列門店共2,446家，輕商務及其他系列門店371家，整體共2,817家門店，淨增加44家。年內，集團繼續集中在優質購物中心中的優越鋪位和奧特萊斯開店，通過最具品牌個性的裝修吸引顧客，提升銷售。於二零二五年十二月三十一日，購物中心店及奧特萊斯店增加至1,135家（二零二四年十二月三十一日：1,036家）。集團新零售業務完成戰略轉型，從過往的庫存清理渠道升級為主力新品銷售平台，年內收入錄得25%的顯著增長。集團持續深耕天貓、京東、抖音等成熟銷售平台的同時，拓展了拼多多、微信視頻號、得物等新興渠道，形成多元化線上銷售網絡。集團同時利用小紅書、微博等社交平台，持續輸出高品質內容，強化內容電商佈局，不僅深化了與消費者的情感聯結，更有效拓展了年輕客群，為新零售業務打開新的增長空間。「多品牌、國際化」發展戰略方面，高端高爾夫服飾品牌「萬星威 MUNSINGWEAR」作為集團多品牌戰略的關鍵佈局，上半年完成交易交割後，下半年在重慶及晉江等地開設首批實體門店，進一步豐富了集團的多元化品牌組合與高端產品線。而集團在馬來西亞開設首家門店的計劃順利落實，並於五月份順利試業。十一月於吉隆坡核心商圈Pavilion Bukit Jalil開設全球首家「未來商業（Future Retail）」概念旗艦店。於二零二五年十二月底已經開設4家門店，所有門店的順利營運，不僅完成了東南亞市場的初步佈局，更為集團後續輻射東南亞市場奠下重要基礎。年內，集團貫徹「簡約不簡單」的設計核心，深化全產業鏈自主研發，打造核心精品單品戰略，專注面料創新、工藝升級與標準制定，加強「技術賦能產品」的競爭優勢的同時更將自身技術積累轉化為全行業可參照的規範標準。面對機遇與挑戰並存的市場環境，中國利郎將保持審慎樂觀的態度，繼續深耕「多品牌、國際化」核心戰略，推進渠道改革、強化產品創新、提升運營效率，鞏固並提升集團於中國男裝行業的領先地位。集團計劃於二零二六年全年淨增加約50至100家門店，開店重點繼續聚焦於優質購物中心及奧特萊斯。同時，集團將進一步鞏固已轉型區域的經營成果，並探索在更多合適區域推廣DTC模式，以強化市場控制力、提升消費體驗。新零售業務方面，集團將持續推進線上渠道佈局，目標二零二六年實現新零售銷售額增長15%以上，並通過內容電商與精準直播觸達更多年輕客群，帶動整體銷售實現10%增長。集團將穩步推進「萬星威 MUNSINGWEAR」的業務發展，計劃在中國內地繼續拓展實體門店網絡，並拓展線上銷售渠道，實現線上線下聯動。國際化拓展方面，繼馬來西亞市場後，集團在菲律賓的公司註冊程序已完成，預計於二零二六年內正式開展業務，逐步完善海外渠道佈局。王冬星主席總結說：「展望二零二六年，全球地緣政治格局依然複雜多變，但中國政府持續推出促進消費、擴大內需的政策措施，為國內市場提供支撐。中國利郎將立足於二零二五年所奠定的穩健基礎，在聚焦『利郎 LILANZ』主系列及『利郎LESS IS MORE』輕商務發展的同時，深化新零售戰略，推進多品牌及海外業務，從而向質量與效率雙升的高階增長階段邁進，並將繼續透過研發創新，持續加強 ESG 建設，實現業務增長與可持續發展並行，致力為股東創造穩健及可持續的回報。」關於中國利郎中國利郎是中國領先的男裝企業之一。作為一家綜合時裝企業，集團設計、採購、生產並以品牌「利郎LILANZ」及「利郎LESS IS MORE」銷售優質男士商務及休閒服裝。其產品主要於中國及海外的廣闊零售及分銷網絡銷售。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 16, 2026 - (ACN Newswire via SeaPRwire.com) – China Lilang Limited (“China Lilang” or the “Company”, together with its subsidiaries, the “Group”; stock code: 1234) today announced its results for the year 2025.Mr. Wang Dong Xing, Chairman and Non-Executive Director of China Lilang, said: “In 2025, against a backdrop of steady macroeconomic recovery and moderate growth in the consumer market, the apparel industry in the Chinese Mainland maintained an overall stable development trajectory despite facing pressure. Amid the broader trend of consumption upgrading, the menswear market is undergoing structural differentiation, with mid-to-high-end segments such as business casual and smart casual becoming core growth drivers. The industry is accelerating its transition from 'quantity-driven competition' towards a stage of high-quality competition centered on 'innovation, quality and sustainable development. China Lilang deepened its presence in the menswear market with its differentiated brand matrix, building a diversified business portfolio through the 'LILANZ' core collection, the 'LESS IS MORE' smart casual collection and the 'MUNSINGWEAR' sports line, to comprehensively meet market demand for high-quality, diverse apparel. At the same time, the Group optimized its omni-channel marketing layout, strengthened online-offline operational synergies, actively expanded into emerging online platforms while accelerating the DTC model offline, and simultaneously advanced its internationalization strategy to enhance brand influence and operational efficiency across multiple dimensions.”During the year, the Group's revenue increased by 11.5% year-on-year to RMB4.07 billion. Revenue from the smart casual and other collections surged by 28.4%, primarily driven by a significant increase in average sales per store and the outstanding performance of new retail channels. Revenue from the core collection grew by 6.0%, mainly due to the initial operational efficiencies generated during the year following the Group's transition to a DTC model after reclaiming distribution rights from distributors starting last year.Gross profit margin increased by 1.9 percentage points year-on-year to 49.6%, mainly due to the increase in average unit price as a result of a higher proportion of direct-to-retail sales, coupled with a smaller one-off deduction from revenue arising from the recovery of distribution rights. Profit attributable to equity shareholders was RMB502 million (2024: RMB460 million), representing an increase of 9.0%. The profit margin attributable to equity shareholders decreased by 0.3 percentage points year-on-year to 12.6%. Earnings per share increased by 9.0% to RMB41.96 cents.The Board has recommended a final dividend of HK13 cents per share (2024: HK9 cents) and a special final dividend of HK3 cents per share (2024: HK3 cents). Together with the interim dividend already paid, the total dividend for the year amounted to HK32 cents per share, maintaining a stable dividend payout ratio.During the year, the Group adhered to its core strategy of ensuring a well-differentiated brand matrix and deepening its presence in the menswear market. The "LILANZ" core collection continued to consolidate its competitive advantage in the traditional menswear market. By optimizing product structure and deepening regional channel deployment and penetration, it further enhanced brand awareness and market share in key markets. Having successfully completed the repurchase and transformation of distribution rights in Northeast China and Jiangsu Province last year, the Group accelerated channel innovation throughout the year, subsequently acquiring the operating rights of first-tier distributors in Shandong Province and Chongqing City. The "LESS IS MORE" smart casual collection, targeting younger consumers, continued to operate under a fully direct-to-retail model, with its store opening strategy focused on shopping malls, which is preferred by consumers to enhance the consumer experience through a precisely tailored store image. As at the end of December 2025, there were 2,446 stores for the core collection and 371 stores for the smart casual and other collections, a total of 2,817 stores with a net increase of 44 stores.During the year, the Group continued to focus on opening stores in prime locations within premium shopping malls and outlet centers, attracting customers and boosting sales through distinctive brand-specific renovations. As at 31 December 2025, the number of stores located in shopping malls and outlet stores increased to 1,135 (31 December 2024: 1,036).The Group completed strategic transformation of its new retail business, upgrading it from an inventory clearance channel into a major new product sales platform. Revenue from this segment recorded a significant increase of 25% during the year. While continuing to strengthen its presence on mature sales platforms like Tmall, JD.com and TikTok, the Group has also expanded into emerging channels such as Pinduoduo, Wechat Channels and Poizon, creating a diversified online sales network altogether.  The Group made full use of social platforms such as Xiaohongshu and Weibo to continuously produce high-quality content to strengthen its content-driven e-commerce strategy. This approach not only deepened the emotional connection with consumers but also effectively expanded the young customer base, opening new growth opportunities for the new retail business.Regarding the "Multi-brands and Internationalization" development strategy, the premium golf apparel brand "MUNSINGWEAR", a key element of the Group's multi-brand strategy, successfully completed its transaction closing in the first half of the year. In the second half, it opened its first batch of physical stores in locations including Chongqing and Jinjiang, further enriching the Group's diversified brand portfolio and premium product lines. Meanwhile, the Group's plan to open its first store in Malaysia was successfully implemented and the first stores commissioned in May. In November, it opened the world's first "Future Retail" concept flagship store at Pavilion Bukit Jalil, a core business district in Kuala Lumpur. By the end of December 2025, 4 stores had been opened. The smooth operation of all stores not only completed the initial layout in the Southeast Asian market but also laid an important foundation for the Group’s subsequent expansion across the region.During the year, the Group adhered to its core design philosophy of "Simplicity but Not Simple", deepening proprietary research and development across its industrial chain. It implemented a core premium product strategy, focusing on fabric innovation, craftsmanship upgrades and standard-setting to strengthen its competitive advantage of "Technology-Empowered Products", while transforming its technological expertise into industry-wide reference standards.Facing a market environment where opportunities and challenges coexist, China Lilang will maintain a prudent yet optimistic stance and continue to pursue its core strategy of "Multi-brands and Internationalization". It will advance channel reforms, strengthen product innovation and enhance operational efficiency, to bolster its leading position in China's menswear industry. The Group plans for  a net increase of approximately 50 to 100 stores in 2026, with the focus remaining on premium shopping malls and outlets. At the same time, the Group will further consolidate the operating results of the regions that have transitioned and explore the possibility of rolling out the DTC model in other suitable regions to deepen market control and elevate consumer experience.In the new retail business, the Group will continue to advance its online channel layout, aiming to achieve over 15% growth in new retail sales in 2026. Through content-focused e-commerce and targeted live streaming, the Group seeks to reach more young customers and drive overall sales growth of 10%.The Group will steadily advance the business development of "MUNSINGWEAR", planning to continue expanding its physical store network in the Chinese Mainland and expanding its online sales channels to achieve online-offline synergy. In terms of international expansion, following its successful entry into the Malaysian market, the Group's company registration process in the Philippines has been completed, with business operations expected to officially commence in 2026, gradually refining its overseas channel layout.Mr. Wang Dong Xing, Chairman of China Lilang, concluded: “Looking ahead to 2026, the global geopolitical landscape remains complex and volatile, but the Chinese government continues to introduce policies and measures to promote consumption and expand domestic demand, providing support for the domestic market. Building upon the solid foundation established in 2025, China Lilang will focus on the development of its 'LILANZ' core collection and 'LESS IS MORE' smart casual collection, while deepening its new retail strategy and advancing multi-brand and overseas businesses, enabling it to advance towards a new stage of growth characterized by improvements in both quality and efficiency. It will also continue to drive R&D  innovation and strength its ESG initiatives, achieving concurrent business growth and sustainable development, striving to create stable and sustainable returns for shareholders."About China LilangChina Lilang is one of the leading PRC menswear enterprises. As an integrated fashion enterprise, the Group designs, sources and manufactures high-quality business and casual apparel for men and sells under brands of 'LILANZ' and 'LESS IS MORE' across an extensive distribution network, mainly in the PRC and overseas. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月16日 - (亞太商訊 via SeaPRwire.com) - 富衛集團有限公司（「富衛集團」或「富衛」）今日公布截至2025年12月31日的年度業績，是在香港上市後的首份全年業績。- 新增業務銷售額按年化新保費計算較2024年上升25% 至24.46億美元。新業務合約服務邊際為14.76億美元，按年增長18%。- 稅後營運利潤增長5%，達4.99億美元。香港特別行政區和澳門特別行政區、泰國和柬埔寨、日本以及新興市場四個地區業務分部皆為集團帶來正面貢獻。- 淨利潤達1.66億美元，自《國際財務報告會計準則》第17號實施後，連續第二年創新高。截至2025年12月31日，富衛集團實現正營運現金流。槓桿比率降至21.3%，接近富衛訂立的15%至20%的目標範圍。- 創造股東價值的重要指標大幅提升，綜合有形權益較2024年12月31日上升18%至87.2億美元；集團內涵價值按年增長19%至68.5億美元。償付能力比率保持穩健，達265%^。- 2025年12月，富衛集團獲納入恒生綜合指數，並被列入滬深港通的合資格股份名單，透過該機制，內地投資者可經由上海及深圳證券交易所以南向交易安排投資香港市場。2026年2月，富衛集團亦獲納入MSCI香港小型股指數。富衛集團行政總裁兼執行董事黃清風表示：「2025 年對富衛集團而言意義非凡。我們成功推行以客為先的策略，並憑藉數碼化營運模式，創下破紀錄的財務業績。我們於2025年7月成功完成首次公開招股，正式成為上市公司，達成了我們長期以來的目標，使富衛得以全面進入資本市場，為未來的發展和增長奠定穩固的基礎。」富衛集團2025年的強勁業績主要由其10個亞洲市場中大部分市場的有機增長所帶動，其中香港特別行政區及澳門特別行政區分部的表現最為突出。日本分部亦錄得穩健表現，在成功的保障業務基礎上，開始拓展退休及儲蓄領域，並推出首款日圓整付保費年金產品。富衛是泰國的市場領導者，儘管2025年業績受利率下行環境影響，以及2024年退出承保企業醫療新業務，泰國分部仍保持穩健地位，為未來優質新業務增長奠定堅實基礎。新興市場分部（涵蓋富衛集團東南亞其餘五個市場）錄得卓越增長，受惠於該地區長期的人口結構、財富累積及數碼化採用趨勢。黃清風補充道：「踏入2026 年，我們將堅定不移地執行既定策略，着眼未來發展，秉持以客為先的理念，深耕高速增長的亞洲市場，並持續聚焦長期可持續發展及盈利能力。」關於富衛集團富衛集團（香港聯合交易所上市代號：1828）為泛亞洲人壽及健康保險公司，服務超過3,800萬名客戶，業務遍及亞洲十個市場，包括印尼人民銀行人壽保險（BRI Life）。富衛秉持以客為先的方針及科技賦能的模式，致力為客戶帶來創新定位、簡單易明的產品和簡單的保險體驗。自2013年成立以來，富衛於部分全球發展最迅速的保險市場營運業務，專注為大眾創造保險新體驗。富衛集團在香港聯合交易所有限公司主板上市，股份代號為1828。如欲了解更多資訊，請瀏覽www.fwd.comFor media inquiries, please contact: groupcommunications@fwd.comSource: FWD Group Holdings Limited所有業績數據均截至 2025年12月31日並與2024年同期比較。集團當地資本總和法覆蓋率、集團內涵價值、綜合有形權益為2025年12月之結餘/比率和增長率。增長率按固定匯率計算，除非另有說明。稅後營運利潤/（虧損）（非國際財務報告會計準則計量指標）、淨利潤/（虧損）及綜合有形權益外，其他數據均未經審計師審核。稅後營運利潤及稅後淨利潤為公司權益持有人應佔部分，並已扣除非控股權益。新增業務銷售以年化新保費100%及整付保費10%組合計算。綜合有形權益按本公司股東應佔本集團權益總額加合約服務邊際結餘（扣除稅項及非控股權益），減無形資產（扣除非控股權益）計算。*按實際匯率計算^按訂明資本要求基準計算 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 16, 2026 - (ACN Newswire via SeaPRwire.com) – FWD Group Holdings Limited (“FWD Group” or “FWD”) today announced its first set of full-year results as a Hong Kong listed company for the 12 months ended 31 December 2025.- New business sales were up 25 per cent to US$2.446 billion compared to 2024 on an annualised premium equivalent (APE) basis. New business contractual service margin (CSM) was US$1.476 billion, with year-on-year growth of 18 per cent.- Operating profit after tax was up five per cent to US$499 million with positive contributions from each of the company’s four geographic reporting segments – Hong Kong SAR & Macau SAR; Thailand & Cambodia; Japan; and Emerging Markets.- Net profit of US$166 million is a record IFRS 17 result and for the second consecutive year, FWD Group was operating cash flow positive as at 31 December 2025. Leverage ratio reduced to 21.3 per cent approaching the company’s target range of 15-20 per cent.- Significantly increased important indicators of shareholder value creation, with comprehensive tangible equity (CTE) up 18 per cent to US$8.72 billion compared to 31 December 2024 and Group embedded value (EV) up 19 per cent year-on-year to US$6.85 billion. A strong capital position was maintained with a 265 per cent solvency ratio^.- In December 2025, FWD Group was added to the Hang Seng Composite Index and the eligible securities list for the Stock Connect programme, where Mainland Chinese investors connect via the Shanghai Stock Exchange and Shenzhen Stock Exchange with Hong Kong market opportunities via a southbound trading mechanism. FWD Group was also included in the MSCI Hong Kong Small Cap Index in February 2026.Huynh Thanh Phong, Group Chief Executive Officer and Executive Director of FWD Group, said, “2025 was a stand-out year for FWD Group. We successfully executed our customer-led strategy, underpinned by our digitally enabled business model. Record financial results were achieved. And of course, we began trading as a publicly listed company, following our July 2025 initial public offering. This fulfilled a long-held objective to ensure FWD Group has full capital market access, as a solid foundation for our future development and growth.”The strong 2025 results were driven by organic growth across most of the 10 Asian markets where FWD Group operates, with a particularly outstanding performance in the Hong Kong SAR & Macau SAR segment.A solid performance was posted in Japan, in a year where FWD began to diversify beyond its successful protection business into the retirement and savings segment, with its first offering – a yen-denominated single premium variable annuity product.As an established market leader in Thailand, FWD remains well positioned to grow quality new business in future, despite headwinds from a lower rate environment which impacted 2025 results, in addition to the 2024 exit from underwriting new business in the corporate care segment.Excellent growth was delivered in the Emerging Markets segment – which is comprised of five of the rest of FWD Group’s Southeast Asian markets – consistent with the longer-term demographic, wealth creation, and digital adoption trends in this region.“With 2026 already underway, we remain firmly focused on executing our strategy as we build for the future – operating with customers at the heart of everything we do in high-growth Asian markets, with a focus on long-term sustainability and profitability,” added Huynh Thanh Phong.About FWD GroupFWD Group (1828.HK) is a pan-Asian life and health insurance business that serves more than 38 million customers across 10 markets, including BRI Life in Indonesia. FWD’s customer-led and tech-enabled approach aims to deliver innovative propositions, easy-to-understand products and a simpler insurance experience. Established in 2013, the company operates in some of the fastest-growing insurance markets in the world with a vision of changing the way people feel about insurance. FWD Group is listed on the main board of the Hong Kong Stock Exchange under the stock code 1828.For more information, please visit www.fwd.comFor media inquiries, please contact: groupcommunications@fwd.comSource: FWD Group Holdings LimitedThe results are for the 12 months ended 31 December 2025 and are compared to the same period in 2024.Group LCSM cover ratio, group embedded value, comprehensive tangible equity values are December 2025 balances/ratios and growth rates are represented accordingly.Growth rates are represented on a constant exchange rate (CER) basis, unless otherwise stated.Except for operating profit/(loss) after tax (non-IFRS measure), net profit/(loss), and comprehensive tangible equity, all other numbers are unaudited. Operating profit after tax and net profit after tax represent the amounts attributable to equity holders of the company and are presented net of non-controlling interests. New business sales are calculated on an annualised premium equivalent (APE) basis, based on 100 percent annualised first year premiums and 10 percent single premiums. Comprehensive tangible equity is calculated as total equity of the Group attributable to shareholders of the Company plus contractual service margin (net of tax and non-controlling interests), minus intangible assets (net of non-controlling interests).* Actual exchange rate basis  ^ Prescribed capital requirement (PCR) basis Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Santo Domingo, Dominican Republic, Mar 14, 2026 - (ACN Newswire via SeaPRwire.com) - In a strategic move to tap into the booming global short-drama market, AdsDrama LTD, an international digital content marketing company registered in Denver with $50 million in capital, has officially launched its tailored short-drama marketing ecosystem in the Dominican Republic. This event marks the company’s key step in expanding its global footprint, aiming to bridge the local content supply gap and build a sustainable digital entertainment model that combines its core strengths in advertising technology and community-driven growth.Short dramas — dozens of 1–3 minute episodes with fast-paced, emotional storytelling—are booming globally, fitting today's fragmented viewing habits. AdsDrama LTD, an international digital content marketing firm, is building a short-drama marketing ecosystem in the Dominican Republic, combining ad technology and community-driven strategies for sustainability.Short Dramas: The Next Digital Entertainment Growth EngineGlobal entertainment has shifted from long-form to short-form content, with short dramas offering advantages: 1–3 minute episodes, engaging storylines, mobile optimization, and higher monetization. The "free viewing + paid unlocking" model effectively retains audiences and generates revenue, fostering a full ecosystem of production, marketing, and commercialization.AdsDrama: Focused on Short-Drama MarketingRegistered in Denver with $50 million capital, AdsDrama's mission is a global short-drama marketing ecosystem integrating ad technology, distribution, data-driven strategies, and community promotion. Its core businesses include short-drama marketing, ad services, commercial operations, custom production, and IP incubation. Operating via "global technology + local operations," it adapts global expertise to local markets.Digital Advertising: The Growth EngineEffective distribution is key for short dramas. AdsDrama promotes content across social media, short-video platforms, portals, and search channels, optimizing campaigns via data analytics. Revenue streams include advertising, paid content, brand partnerships, and IP commercialization—forming the industry's financial foundation.Community-Driven "Co-Builder" ModelAdsDrama's "co-builder ecosystem" invites local participants to share content, provide market feedback, and expand reach. In return, co-builders get marketing materials, data access, and training—leveraging community trust, which outweighs algorithmic traffic in Latin America.User Experience & VIP StructureNew users get a free trial (RD$25–RD$60) to learn the platform's workflow and revenue model. For deep engagement, VIP levels (e.g., VIP3: RD$16,200 participation, daily returns of RD$270–RD$648 for 730 days) offer tiered benefits, with automatic revenue calculation and principal return options post-cooperation.Why the Dominican Republic?The country is a key market due to its young population (high digital entertainment demand), widespread mobile internet usage, and a gap in professionally produced short dramas—creating ideal conditions for ecosystem development.Three-Phase Development StrategyAdsDrama's 3-year plan: Phase 1 (1–6 months): Launch flagship dramas, build user communities, optimize marketing; Phase 2 (7–18 months): Expand promotion, improve operations, diversify revenue; Phase 3 (19–36 months): Open to independent creators, build a comprehensive ecosystem, and expand to the Caribbean and Latin America.The Future of the Digital Content EcosystemAs mobile internet continues to evolve, the digital entertainment industry is undergoing constant transformation.Short videos changed how audiences consume media. Short dramas may represent the next stage of this evolution - combining storytelling, advertising, and digital commerce in a single content format.Companies like AdsDrama LTD believe that the future of digital content will rely on the integration of multiple elements:creative storytellingtechnology infrastructuredata-driven marketingcommunity-based promotionIn this ecosystem:creators focus on producing contentplatforms provide technology and marketing toolscommunities help amplify distributionTogether, these elements form a sustainable and scalable digital content economy.Short dramas represent the next evolution of digital entertainment, integrating storytelling, advertising, and commerce. AdsDrama's focus on infrastructure, community, and data will drive the industry's growth, with the Dominican Republic and Latin America at the forefront of this transformation.Media contactBrand: AdsDrama LTDContact: Media teamWebsite: https://www.adsdrama.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

佛羅里達州邁阿密, 2026年3月13日 - (亞太商訊 via SeaPRwire.com) - General MRO Aerospace（GMA）今日宣布，已正式獲得中國民用航空局（CAAC）的認證，授權該公司為中國註冊飛機的部件提供維修、保養及大修（MRO）服務。此項認證標誌著 General MRO Aerospace 國際發展戰略的重要里程碑，並進一步印證了該公司對最高安全標準、品質及法規遵循的承諾。「取得 CAAC 認證是 General MRO Aerospace 持續拓展全球業務版圖的重要一步，」General MRO Aerospace 總裁 Jonathan Cornell 表示。「這項批准彰顯了我們品質體系的實力、技術專長，以及對支持全球航空公司與 MRO 合作夥伴的承諾。」獲得民航局（CAAC）批准後，GMA 得以依照中國航空監管要求，為各類飛機組件提供維修與大修服務。認證過程包含對該公司設施、品質管理系統、技術程序及法規遵循計畫的全面審核。General MRO Aerospace 目前已遵循 FAA Part 145、EASA、CAA 及 CAAT 品質標準營運，此次新增的 CAAC 認證將使該公司能更完善地服務亞太航空市場中的營運商、租賃商及維修服務供應商。「隨著全球對高品質部件維修服務的需求日益增長，這項認證強化了我們支援在中國及整個地區營運客戶的能力，」康奈爾補充道。「我們期待與中國航空公司及航空組織建立堅實的合作夥伴關係。」General MRO Aerospace 專精於複雜飛機部件的維修與大修，憑藉可靠的週轉時間、卓越的技術實力及以客戶為中心的服務，為全球商用及貨運營運商提供支援。關於 General MRO AerospaceGeneral MRO Aerospace 是一家總部位於美國、通過 AS9110 及 ISO 9001 認證的航空維修、保養與大修服務供應商，專門為全球商用飛機營運商提供部件維修與支援服務。憑藉FAA Part 145、EASA、CAA、CAAT及CAAC認證，該公司為全球航空公司、租賃公司及MRO合作夥伴提供高品質的技術解決方案、反應迅速的客戶服務以及可靠的維修週期。媒體聯絡人Michelle Torres行銷專員General MRO AerospaceMtorres@GeneralMROAerospace.com www.GeneralMROAerospace.com 消息來源：General MRO Aerospace Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

MIAMI, FL, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) - General MRO Aerospace (GMA) today announced that it has officially received certification from the Civil Aviation Administration of China (CAAC), authorizing the company to perform maintenance, repair, and overhaul (MRO) services for components on Chinese-registered aircraft.The certification marks a significant milestone in General MRO Aerospace's international growth strategy and further validates the company's commitment to the highest standards of safety, quality, and regulatory compliance."Achieving CAAC certification is an important step forward for General MRO Aerospace as we continue to expand our global footprint," said Jonathan Cornell, President of General MRO Aerospace. "This approval demonstrates the strength of our quality systems, our technical expertise, and our commitment to supporting Airline and MRO partners worldwide."The CAAC approval allows GMA to provide repair and overhaul services for a range of aircraft components in accordance with Chinese aviation regulatory requirements. The certification process included a comprehensive audit of the company's facilities, quality management system, technical procedures, and regulatory compliance programs.General MRO Aerospace already operates under FAA Part 145, EASA, CAA, and CAAT quality standards, and the addition of CAAC certification enables the company to better serve operators, lessors, and maintenance providers across the Asia-Pacific aviation market."With increasing global demand for high-quality component repair services, this certification strengthens our ability to support customers operating in China and throughout the region," Cornell added. "We look forward to building strong partnerships with Chinese airlines and aviation organizations."General MRO Aerospace specializes in the repair and overhaul of complex aircraft components, supporting commercial and cargo operators worldwide with reliable turnaround times, technical excellence, and customer-focused service.About General MRO AerospaceGeneral MRO Aerospace is an AS9110 and ISO 9001 accredited U.S.-based aviation maintenance, repair, and overhaul provider specializing in component repair and support services for commercial aircraft operators worldwide. Operating under FAA Part 145, EASA, CAA, CAAT, and CAAC certification, the company delivers high-quality technical solutions, responsive customer service, and dependable turnaround times to airlines, leasing companies, and MRO partners around the globe.Media ContactMichelle TorresMarketing SpecialistGeneral MRO AerospaceMtorres@GeneralMROAerospace.comwww.GeneralMROAerospace.comSOURCE: General MRO Aerospace Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, CHINA, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the “Product”) has been approved for marketing in China by the National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a novel, oral HypoxiaInducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients.The approval of Desidustat Tablets will further strengthen the Group’s overall layout in the field of nephrology, and synergize with the marketed innovative drug Velphoro (Sucroferric Oxyhydroxide Chewable Tablets, indicated for CKD hyperphosphatemia). Through the efficient linkage of nephrology expert resources and channel networks, the Group is expected to rapidly promote the large-scale clinical application of Desidustat Tablets, providing differentiated treatment options for Chinese CKD patients with renal anaemia and making a positive contribution to the Group’s performance.More information about Desidustat Tablets and Renal AnaemiaAs a novel oral HIF-PHI, the Product’s mechanism of action promotes erythropoiesis through increasing endogenous erythropoietin, improving iron availability and reducing hepcidin. Its China Phase III clinical trial has demonstrated positive results. The primary endpoint of the haemoglobin (Hb) mean change from baseline to Week 7-9 has indicated that, Desidustat is more effective than placebo in increasing Hb level. Results from the extension study demonstrate that the Product can maintain Hb level within the target range over the long term with acceptable safety. In addition, the Product significantly reduces hepcidin levels and ameliorates iron metabolism disorders.There is still a large unmet need in the treatment of anaemia in CKD patients in China. It is estimated that there are more than 120 million CKD patients in China[1]. Anaemia is one of the frequent complications of CKD, which exhibits a progressively increasing incidence with disease progression. A survey in China showed that the prevalences of anaemia in patients at CKD stage 1 to 5 were 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively[2]. The target-achieving rate (the Hb level reaching the target value (110~120g / L)) has increased to 51.5% for haemodialysis CKD patients with anaemia[3], but is still only 8.2% for anaemia patients in non-dialysis CKD[4]. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia.Desidustat Tablets have been approved for marketing in India.CMS INTERNATIONAL DEVELOPMENT AND MANAGEMENT LIMITED, a wholly-owned subsidiary of the Group, obtained an exclusive license for the Product from Zydus Lifesciences Limited (earlier known as Cadila Healthcare Limited) pursuant to a License Agreement with an effective date of 20 January 2020.The Group adheres to its core strategy of “innovation-driven”, having established a tiered and multi-dimensional innovation product portfolio with abundant reserves: 7 new drugs have been approved for marketing, 6 are currently under marketing review, and nearly 20 projects are about to initiate or are progressing through clinical trials. Through a dual-engine innovation approach combining collaborative development and in-house R&D, the Group continuously enriches its innovative pipeline centered on first-in-class (FIC) and best-in-class (BIC) products, efficiently advancing clinical development and commercialization. Moving forward, CMS will remain clinical needs-driven to deliver more quality pharmaceutical solutions, steadfastly advancing toward the goal of becoming a specialty-focused, innovation-excellent multinational pharmaceutical enterprise.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference1. ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-62. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2014 Revised Edition)[J]. Chinese Journal of Nephrology, 2014, 30(9): 712-716. DOI: 10.3760/cma.j.issn.1001-7097.2014.09.0153. 19th CSN Critical Care & Blood Purification Congress, Chinese Medical Association (July 2-5, 2025)4. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2018 Revised Edition)[J]. Chinese Journal of Nephrology, 2018, 34(11): 860-866. DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) – CITIC Resources Holdings Limited (hereinafter referred to as CITIC Resources or the Company, or the Group when its subsidiaries are included; Stock Code: 1205.HK) has announced its annual results for the year ended 31 December 2025 (the “Year”). During the Year, the Group actively responded to the complex international environment and cyclical industry pressures. Systematically advancing initiatives in “upstream asset deployment, expansion of trading business, and enhancement of production and operations”, the Group deepened its dual-engine development model of “investment + trading”, stabilised its core operations, cultivated a second growth curve, and demonstrated robust operational and developmental resilience.As a key growth driver for the Group, the oil and gas trading business within the import and export segment expanded steadily during the Year, achieving a significant milestone with a trading volume exceeding 20.0 million barrels and revenue reaching approximately HK$11.34 billion. Meanwhile, the Group broke the long-standing monopoly of the sales channel of crude oil, enhancing the market value of its oil and gas properties. In the non-oil-and-gas business, the Group consistently prioritises refined and proactive management of its equity investments as a core task and actively conveyed its philosophy of improving quality and enhancing efficiency to the operators. Notably, the value of shares held in Aloca Corporation (“Aloca”) increased by approximately 46.3% during the Year. On the oil and gas front, focusing on refined reservoir management and continuous scientific research breakthroughs, the Group achieved stable production and increased reserves. It comprehensively deepened lean management throughout the production process, coupled with the implementation of cost-reduction and efficiency-enhancement measures, propelled continuous improvements in management standards and operational efficiency across all phases of oil and gas projects from exploration, development to production.During the Year, the Group achieved revenue of approximately HK$14.96 billion (2024: approximately HK$9.50 billion), representing a year-on-year increase of approximately 57.6%. Impacted by factors such as a decline in the average selling price of crude oil and coal, and higher raw material costs, profit attributable to ordinary shareholders of the Company amounted to approximately HK$0.17 billion (2024: HK$0.57 billion). Despite that, all of the Group’s segments recorded profits for the Year and the Group continued to maintain a strong financial position with cash and deposits of approximately HK$3.52 billion as at 31 December 2025 (31 December 2024: HK$2.03 billion). As at 31 December 2025, the Group had total assets of approximately HK$14.61 billion, and net assets attributable to ordinary shareholders of the Company of approximately HK$8.79 billion. The gearing ratio and interest-bearing debt ratio were approximately 38.8% and 23.5% respectively, with a return on equity (annualised) of approximately 2.0%.As part of its efforts to optimise its asset structure, the Group disposed of shares in Alcoa in January and March 2026, totalling approximately 2.17% of Alcoa’s total issued shares[1]. By seizing the opportunity to monetise its investment at a high valuation, the Group continues to create greater value for its shareholders.Mr. Hao Weibao, Executive Director, Chairman and Chief Executive Officer of CITIC Resources, said: “Looking ahead to 2026, the Group will focus on key areas such as the development, production and trading of oil and gas, as well as investments in the aluminum industry chain, deepen synergies among trading, investment and production management, and continue to implement the business strategy of consolidating the existing core business and pursuing dual-engine expansion through ‘investment + trading’.To consolidate our existing principal business, the Group will continue to enhance lean production and operational management to increase reserves and output, while steadily expanding production and sales scale. The Group will also intensify the introduction and application of new processes and technologies, leveraging technological innovation to empower high-quality development of our core businesses and reinforce our core growth foundation.On the dual-engine driver of ‘investment + trading’ expansion front, the Group will continue to track and position in high-quality oil and gas assets and the aluminium-centric key metals industry chain. Trading operations and investment projects will be deeply integrated: the investment arm will secure equity resources, while the trading arm will achieve market-oriented sales. This approach will also enhance our market sensitivity, enabling us to identify and acquire high-quality upstream resources and assets, thereby creating a virtuous cycle in which ‘investment acquires resources and trading converts value’. The Group is committed to implementing these development strategies and will continue to deliver long-term and stable returns to our shareholders.”[1]Details regarding the disposal were disclosed in the announcements and circular dated 16 January, 6 February, and 5 March.For details of CITIC Resources’ 2025 annual results, please refer to the Group’s annual results announcement on the Hong Kong Stock Exchange and the Group’s website.About CITIC Resources Holdings Limited (Stock Code: 1205.HK)CITIC Resources Holdings Limited has been listed on the Hong Kong Stock Exchange since 1997. Principal activities of CITIC Resources include the exploration, development and production of oil and coal, investments in bauxite mining, alumina refinery, aluminium smelting and oil and gas trading. CITIC Limited is the largest shareholder with about 59.5% interest in CITIC Resources. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月13日 - (亞太商訊 via SeaPRwire.com) - 中信資源控股有限公司（「中信資源」或「公司」，連同其附屬公司統稱為「集團」；股份代號：1205.HK）公布截至2025年12月31日止年度（「年内」）之全年業績。年內集團積極應對複雜國際市場環境及行業週期性波動壓力，系統推進「上游資產布局、貿易業務拓展、生產運營提質」工作，深化「投資+貿易」雙輪驅動發展模式，穩固經營基本盤，培育第二增長曲線，彰顯了強大的經營和發展韌性。作為集團主要的增長引擎之一，進出口業務板塊中的油氣貿易業務年內穩步拓展，貿易量超2,000萬桶，實現貿易收入約113.4億港元，達成重大里程碑。集團同時打破權益油銷售多年被壟斷局面，提升權益油市場價值。非油業務方面，集團始終將參股項目的精細化、主動化管理作為核心工作，向作業方傳導提質增效理念，其中所持有的美國鋁業公司（「美國鋁業」）股份價值年內增長46.3%。油氣業務方面，集團以精細化油藏管理與持續科研攻關為核心，實現穩產增儲；全面深化生產過程的精益管理，落實降本增效舉措，推動油氣項目在勘探、開發及生產各環節的管理水平和運營效益持續提升。年內，集團實現營業收入約149.6億港元（2024年：約95.0億港元），同比增長約57.6%。受原油及煤炭的平均售價下降、原材料成本上升等因素影響，本公司普通股股東應佔溢利約1.7億港元（2024年：約5.7億港元）。儘管如此，集團全部分類於本年度錄得溢利，且於2025年12月31日繼續維持穩健的財務狀況，現金及存款約為35.2億港元（2024年12月31日：20.3億港元）。截至2025年12月31日，集團總資產146.1億港元，歸母淨資產約87.9億港元，資產負債率約38.8%，有息負債率約23.5%，淨資產收益率約2.0%。作為優化資產結構的舉措之一，集團於2026年1月及3月先後減持美國鋁業股份，累計出售相當於其已發行股份總數約2.17%。集團精準把握高位變現的時機，持續為股東創造更大價值[1]。中信資源執行董事、主席兼行政總裁郝維寶先生表示：「展望2026年，集團將聚焦油氣開發生產與貿易、鋁產業鏈投資等關鍵領域，深化貿易、投資與生產運營協同，持續貫徹『夯實存量主業、「投資+貿易」雙輪拓展』的經營策略。夯實存量主業方面，集團將持續深化精益生產運營管理，實現增儲上產，穩步擴大產銷規模；同時加大新工藝、新技術引進與應用力度，以科技創新賦能主業高質量發展，築牢核心發展根基；『投資+貿易』雙輪拓展方面，持續跟蹤和佈局優質油氣資產及以鋁為核心的關鍵金屬產業鏈，貿易業務與投資項目形成深度聯動，投資端獲取權益資源，貿易端實現市場化銷售，同時形成市場觸角，識別並獲取位於產業鏈上游的優質資源資產，形成『投資獲取資源，貿易轉化價值』的良性循環。集團將致力落實此等發展戰略，持續為廣大股東創造長期穩定的價值回報。」[1]出售事項的相關詳情可見於1月16日、2月6日及3月5日刊出的公告及通函。有關中信資源2025年全年業績的詳情，請參考集團在香港聯交所及其網站的全年業績公告。關於中信資源控股有限公司（股份代號：1205.HK）中信資源控股有限公司自1997年起，在香港聯合交易所上市。中信資源的主要業務包括石油和煤的勘探、開發和生產，於鋁土礦開採、氧化鋁冶煉和電解鋁領域的投資及油氣貿易。中國中信股份有限公司持有中信資源約59.5%的股權，為中信資源最大股東。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2026年3月13日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司(867.HK/8A8.SG)（「康哲藥業」）欣然宣佈，腎性貧血新藥德昔度司他片（原名：德度司他片）（「產品」）上市許可申請已於2026年3月13日獲得中國國家藥品監督管理局（NMPA）批准。產品為一種創新型口服低氧誘導因子-脯氨醯羥化酶抑制劑（HIF-PHI），適用於非透析的成人慢性腎臟病（CKD）患者的貧血治療。德昔度司他片獲批上市，將進一步強化康哲藥業在腎病專科領域的整體佈局，並與處於商業化階段的創新藥維福瑞（蔗糖羥基氧化鐵咀嚼片，用於CKD高磷血症）協同增效。通過腎內科專家資源與渠道網絡的高效聯動，康哲藥業有望快速推動德昔度司他片的規模化臨床應用，為中國CKD腎性貧血患者提供差異化的治療選擇，為集團業績帶來積極貢獻。關於德昔度司他片和腎性貧血的更多信息作為一種創新型口服HIF-PHI，產品作用機制為通過增加內源性促紅細胞生成素的生成、改善鐵的利用率和降低鐵調素的水平來促進紅細胞生成。其中國III期臨床試驗取得了積極結果。主要研究終點血紅蛋白（Hb）水平（第7-9周Hb平均值相對於基線的變化）結果顯示，試驗組優於安慰劑組。擴展期研究結果顯示，產品可使Hb水平長期維持在達標水平，且安全性良好。此外，產品還可以顯著降低鐵調素水平，糾正鐵代謝紊亂。中國CKD貧血治療領域仍存在顯著的未被滿足需求。據估計，中國有超過1.2億CKD患者[1]，貧血作為其常見併發症之一，發生率隨病程進展呈逐步升高趨勢。國內一項調研顯示，CKD1～5 期患者貧血患病率依次為：22.0%、37.0%、45.4%、85.1%和98.2%[2]。血液透析CKD貧血患者的治療達標率（Hb水平達到靶目標值（110～120 g/L））已提升至51.5%[3]，但對於非透析CKD貧血患者來說仍僅為8.2%[4]。產品採用口服給藥，有望提高患者的治療順應性，有望滿足CKD貧血領域未被滿足的治療需求。產品已在印度獲批上市。康哲藥業之全資附屬公司康哲國際發展管理有限公司通過生效日為2020年1月20日的《許可協議》從Zydus Lifesciences Limited（前稱為Cadila Healthcare Limited）處獲得產品的獨家許可權利。康哲藥業堅持 「創新驅動」 核心戰略，已構建起梯隊銜接、儲備充足的立體化創新產品矩陣：7款新藥獲批上市、6款正處於上市審評階段、近20個項目即將開展/正在推進臨床試驗。康哲藥業通過「合作開發+自主研發」雙輪驅動創新，持續豐富以全球首創（FIC）、同類最優（BIC）產品為核心的創新管線，高效推進臨床開發與商業化落地。未來，康哲藥業將繼續以臨床需求為導向，提供更多優質醫藥解決方案，堅定向專科聚焦、創新卓越的國際化醫藥企業邁進。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化，把控產品全生命週期管理的開放式平臺型企業，致力於提供有競爭力的產品和服務，滿足尚未滿足的醫療需求。康哲藥業專注於全球首創（FIC）及同類最優（BIC）的創新產品，並高效推進創新產品臨床研究開發和商業化進程，賦能科研成果向診療實踐的持續轉化，造福患者。康哲藥業聚焦專科領域，擁有被驗證的商業化能力，廣泛的渠道覆蓋和多疾病領域專家資源，核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展，以鞏固心腎代謝/消化/眼科/皮膚健康業務競爭力，帶來專科規模效率，其中皮膚健康業務（德鎂醫藥）已成為其細分領域的龍頭企業，並擬於聯交所獨立上市。同時，康哲藥業持續推動研產銷全產業鏈在東南亞及中東區域運營發展，以獲取新興市場的增量，助力集團實現高質量可持續發展。參考文獻/資料1.ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-62.腎性貧血診斷與治療中國專家共識（2014修訂版）[J]. 中華腎臟病雜誌, 2014, 30(9): 712-716. DOI: 10.3760/cma.j.issn.1001-7097.2014.09.0153.中華醫學會腎臟病學分會第十九屆重症腎臟病與血液淨化大會（2025年7月2-5日）4.腎性貧血診斷與治療中國專家共識（2018修訂版）[J]. 中華腎臟病雜誌, 2018, 34(11): 860-866. DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣，非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療信息，請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請，不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制，但康哲藥業並無進行任何說明或保證、明述或暗示，或其他表述，對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述，該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證，存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測，康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) – uSmart Securities Limited ("uSMART Securities/the Company") is pleased to announce the official opening of its ninth and tenth physical service centres in Tai Wai and Tuen Mun. Within just one year, uSMART Securities has expanded its Hong Kong service network to 12 physical service centres, surpassing industry benchmarks and actively implementing its "Online x Offline" (O2O) community finance strategy. This expansion solidifies its position as the “No.1 Hong Kong Funded Fintech Brokerage^” and further enhances brand influence.Promoting Accessible Community Financial ServicesThe Tuen Mun branch held a simple yet meaningful opening ceremony today, marking the official commencement of services and a new chapter in the Company's development. Mr. Neo Lee, Executive Director of uSMART Securities, stated: "The opening of the Tai Wai and Tuen Mun branches represent a crucial strategic move in our commitment to local communities and advancing community-oriented services. We focus not only on network coverage but also on connecting with the community, upholding our 'customer-centric' philosophy. By bridging the gap with residents, we are advancing toward our goal of 'seamless coverage across Hong Kong'."(From left to right: Business Development Manager of uSMART Securities, Executive Director of Research Department of uSMART Securities, Executive Director of uSMART Securities, Marketing Director of uSMART Securities and Business Development Director of uSMART Securities)(From left to right: Business Development Manager of uSMART Securities, Executive Director of Research Department of uSMART Securities, Executive Director of uSMART Securities, Marketing Director of uSMART Securities and Business Development Director of uSMART Securities)Comprehensive Coverage Across Hong Kong 18 DistrictsAiming to accelerate the goal of becoming "the Fintech brokerage with the most service centres in Hong Kong," uSMART Securities will open branches in core areas, Kai Tak and Mong Kok in the second quarter. The company is also actively exploring pop-up stores in shopping malls and participating in various exhibition booths. Through multi-channel engagement with customers across different districts, the company aims to refine its regional presence, enabling citizens across all 18 districts to easily access professional and personalized investment and wealth management services, seamlessly integrating financial experiences into daily life.Diversified Investment ProductsAt the opening ceremony, Neo revealed that uSMART Securities has recently obtained a futures trading license and is preparing to launch futures trading services by mid-year. Upon launch, clients will be able to trade futures, including index futures, commodity futures, and currency futures via the uSMART platform. This expansion provides investors with a more comprehensive range of investment products covering long-term, medium-term, and short-term investments, as well as low, medium, and high expected returns, catering to diverse client needs.Futures services will be fully integrated into the existing uSMART APP trading platform, allowing clients to trade US and Hong Kong stocks, futures, ETFs, funds, and discretionary investment products from a single APP. This enables diversified asset allocation, risk management, and wealth enhancement services, allowing clients to utilize capital efficiently and manage investment portfolios flexibly, truly achieving "one-stop wealth management with comprehensive asset allocation."Promoting Investment Education and Enhancing Client InteractionuSMART Securities is also committed to advancing investor education, regularly hosting various online and offline investment seminars and thematic events such as wine tastings and cocktail workshops. These initiatives deepen client engagement and relationships, enhancing customer retention and loyalty.Meanwhile, a new financial channel led by stock commentator and Executive Director of Research, Mr. Dickie Wong, will officially launch next Monday (March 16). Before the market opens and midday close on every Hong Kong stock trading day, a professional team will provide you with real-time analysis of market dynamics and investment opportunity. uSMART Securities aims to foster closer interaction, helping clients refine their practical skills, optimize investment decisions, and build a more comprehensive platform for learning and practice.Expanding Team SizeIn line with rapid business growth, uSMART Securities is actively advancing local talent recruitment and training. The company expects to increase its workforce by 30% over the next two years across areas including branch operations, product design, wealth management, compliance and risk control, and marketing operations. This expansion aims to enhance team scale and professional capabilities, driving steady business growth.Looking ahead, uSMART Securities will continue to optimize trading experiences and strengthen synergies between offline service points and community activities, further solidifying its leading position in financial technology. By combining innovative technology with community networks, the company strives to provide more convenient and personalized wealth management services for investors of all ages and experience levels, promoting the popularization and intelligent development of Hong Kong's financial ecosystem.^”No.1 Hong Kong Funded Fintech Brokerage" is based on TradeGo Cloud data, with uSMART Securities ranking first in monthly transaction volume among local Hong Kong-funded internet brokers for over a year as of February 2026.About uSMART:uSMART Securities is a leading Hong Kong Funded Fintech Brokerage founded in 2018. Over the past eight years, it has pioneered the fusion of technology and finance, offering stocks trading, asset management, and wealth management solutions. Its proprietary platforms, uSMART HK APP and uSMART SG APP, operated by uSMART Securities (Hong Kong) and uSMART Securities (Singapore) respectively. It supports investments in Hong Kong stocks, US stocks, A-shares (via Shanghai and Shenzhen Stock Connect), Singapore Stocks, Japan Stocks, UK Stocks, US options, ETFs, Funds, Bonds, Asset Management, Structured Notes, Futures, Crypto, Precious Metals, Gold, and forex. Furthermore, uSMART is equipped with a highly professional research and asset management team that offers asset management, wealth management, securities brokerage, institutional business, LPF services, and investment banking, dedicated to serving ultra-high-net-worth individuals and families, corporations, investment institutions, fund companies, and other brokerage firms with comprehensive asset management solutions.For details please visit: https://hk.usmartglobal.comFor any media queries, please contact:Carrie Wong9788 4665carriewong@usmart.hk Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月13日 - (亞太商訊 via SeaPRwire.com) - uSMART盈立證券有限公司（下稱「盈立證券」或「本公司」）欣然宣佈，第九及第十間實體服務中心正式進駐大圍及屯門，短短一年內，盈立證券全港服務網絡已增至12間服務中心，超越全行，積極實踐「線上 x 線下」（O2O）社區金融策略，鞏固港資科技券商No.1^地位，進一步擴大品牌影響力。推動社區金融服務普及化屯門分行今日舉行簡單而隆重的開幕典禮，標誌該分行正式投入服務，為本公司的發展里程寫下嶄新一頁。盈立證券執行董事李建翰先生 (Neo) 表示：「大圍及屯門分行的開業，是我們心繫本地社區，持續推動社區化服務的重要戰略性部署。我們不僅追求網絡覆蓋率，更重視與社區的連結，貫徹『以客為本』的理念，拉近與居民的距離，朝『全港無縫覆蓋』的目標邁進。」(左起︰盈立證券業務拓展經理林向尊先生、盈立證券研究部執行董事黃德几先生、盈立證券執行董事兼機構業務負責人李建翰先生、盈立證券香港市場部總監黃曉霖小姐及盈立證券業務拓展總監鄧永麟先生)(左起︰盈立證券業務拓展經理林向尊先生、盈立證券研究部執行董事黃德几先生、盈立證券執行董事兼機構業務負責人李建翰先生、盈立證券香港市場部總監黃曉霖小姐及盈立證券業務拓展總監鄧永麟先生)全港18區服務全覆蓋為加速實現『全港最多服務中心的科技券商』的目標，盈立證券將於第二季在核心地區 ─ 啟德及旺角開設分行，並積極物色商場期間限定店及參與各類展會攤位，希望透過多渠道接觸不同地區客戶，藉此進一步完善地區性佈置，讓全港18區市民皆可輕鬆獲取專業、個性化的投資理財服務，把金融體驗融入日常生活。」投資產品多元化Neo在開幕典禮上透露，盈立證券早前更取得期貨交易牌照，並正籌備於年中正式推出相關期貨交易業務。屆時客戶可透過uSMART平台進行期貨交易，涵蓋指數期貨、商品期貨及外匯期貨等，為投資者提供更全面的投資產品，長、中、短線投資以及低、中、高預期回報俱備，滿足不同客戶的需求。期貨業務將全面整合至現有的 uSMART APP交易平台，客戶可使用同一個APP買賣美港股、期貨、ETF、基金及全權委託投資產品等，即可享受多元資產配置、風險管理及財富增值服務，高效地運用資金，靈活地管理投資組合，真正實現「一站式理財．全方位佈局」。推動投資教育 強化客戶互動體驗盈立證券對推動投資者教育亦不遺餘力，定期舉辦不同類型的線上及線下的投資講座，及主題活動，如葡萄酒品鑑會及雞尾酒工作坊，深化與客戶的互動與關係，提升客戶黏度，增加客戶忠誠度。同時，由資深股評人兼研究部執行董事黃德几先生（Dickie）親自帶領的全新財經台，將於下周一（3月16日）強勢啟播，每個港股交易日的早上開市及中午收市前，由專業團隊為您即時剖析市場動態與投資機遇。盈立證券期望透過更緊密的互動，協助客戶精進實戰技巧、優化投資決策，打造更完善的學習與實踐平台。擴大團隊規模　配合業務高速發展，盈立證券正積極推進本地人才招募與培訓，預計未來兩年職位數量將增加30%，涵蓋前線分行、產品設計、財富管理、合規風控及市場營運等範疇，全面擴大團隊的規模及專業能力，推動業務穩健成長。 展望未來，盈立證券將持續優化交易體驗，並加強線下網點與社區活動的協同效應，進一步鞏固在金融科技領域的領先地位；同時結合創新科技與社區網絡，為不同年齡及資歷的投資者提供更便捷、更具溫度的理財服務，推動本地金融生態朝普及化及智能化發展。^「港資科技券商No.1」是取自捷利金融雲截至2026年2月為止連續超過一年數據， uSMART盈立證券為香港本地港資互聯網券商月成交總額排行第1。關於uSMART盈立證券：盈立證券 是一間領先科技港資券商，成立於2018年，8年來憑藉卓越的戰略規劃和創新能力，致力於將科技與金融深度融合，業務範圍涵蓋證券、資產管理、財富管理等領域，為全球投資者獨家研發了金融證券交易平台 uSMART HK APP和 uSMART SG APP，分別由盈立證券（香港）和盈立證券（新加坡）提供服務。集團APP 支持港股、美股、A股（滬深港通）、新加坡股票、日本股票、英國股票、美股期權、ETF、基金、債券、資管、結構化票據、期貨、加密貨幣、貴金屬、黃金和外匯等多元化的投資交易服務，此外更為超高淨值個人與家族、企業提供度身訂制服務，打造全方位綜合性資產管理解決方案。詳情可瀏覽 https://hk.usmartglobal.com傳媒查詢：黃曉霖 Carrie Wong9788 4665carriewong@usmart.hk Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, CHINA, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) - On 12 March 2026, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health, which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) has its innovative prescription medicine ruxolitinib phosphate cream (Lumirix®) (the “Product”, marketed as Opzelura® in the U.S., Europe and Canada) recorded the initial prescriptions for vitiligo patients across 30 provincial-level regions. The prescriptions cover approximately a thousand influential public and private medical institutions in the field of skin health and disease management, including Huashan Hospital, Fudan University, Shanghai Skin Disease Hospital, Dermatology Hospital of Southern Medical University, Second People's Hospital of Chengdu, The First Bethune Hospital of Jilin University, The Second Xiangya Hospital of Central South University, United Family Healthcare Group, among others*. Meanwhile, the Product has become concurrently accessible via over 1,300 offline drugstores as well as JD.com e-commerce platform. *Hospital rankings are listed in no particular order.As the first topical JAK inhibitor approved in China for the treatment of vitiligo, ruxolitinib phosphate cream has officially launched its large-scale clinical application today, marking a breakthrough in China’s vitiligo treatment landscape and ushering in a new era of precision targeted therapy for vitiligo. Supported by safety and efficacy fully demonstrated in clinical studies, the Product is expected to bring new hope for repigmentation to millions of vitiligo patients.The rapid commercialization progress of ruxolitinib phosphate cream underscores strong product operation capabilities of CMS (including Dermavon), while also reflecting the robust supports from China’s regulatory reforms in accelerating patient access to clinically urgently needed innovative drugs. Benefiting from the integrated healthcare ecosystem of the Hainan Free Trade Port and the “Urgently Needed Imported Drugs for Clinical Use” policy, the Product initiated pilot clinical use in August 2023 at Boao Super Hospital within the Boao Lecheng International Medical Tourism Pilot Zone. Pilot usage subsequently expanded to designated medical institutions across the Guangdong–Hong Kong–Macao Greater Bay Area, Beijing-Tianjin region and other regions. In accordance with the relevant regulations of China’s real-world data application pilot project, as well as supported by the Hainan Provincial Medical Products Administration and the Administration of the Boao Lecheng International Medical Tourism Pilot Zone, the Product has accumulated real-world clinical data in China under pilot application, significantly accelerating its clinical, registration and approval timelines. The Product received its Drug Registration Certificate on January 30, 2026 (approval date: January 27, 2026).Following its approval, in less than 1.5 months (including the Chinese New Year holiday), the initial prescriptions for ruxolitinib phosphate cream have been issued across multiple regions and hospitals, reflecting the highly efficient collaboration and concerted efforts among CMS teams, regulatory authorities and business partners. With robust support from the cross-departmental coordination mechanism of the Beijing Daxing Airport Economic Zone Joint Administrative Committee, once import conditions were met, the Product completed customs clearance approval, sampling and related customs procedures within 24 hours, and obtained the drug testing report within 7 working days, representing efficient execution and acceleration for the innovative drugs in China. During this process, the Beijing Municipal Medical Products Administration proactively provided end-to-end policy guidance; the government service center has efficiently completed customs clearance filing; the Beijing Institute for Drug Control has conducted methodological pre-testing to accelerate timelines for innovative drug, and continuous worked during the Chinese Spring Festival; and Daxing Airport Customs provided specialized pre-guidance on declaration and swiftly completed customs review and release. Through parallel workflows and coordinated execution, all parties collectively pressed the “fast-forward button” for the Product’s commercialization, helping this urgently needed innovative therapy reach patients faster.As the Product enters the large-scale clinical application stage, it is expected to further strengthen Dermavon’s comprehensive dermatology solutions and brand value. Building on its leadership in skin health, Dermavon will continue to improve accessibility of ruxolitinib phosphate cream to benefit more vitiligo patients and steadfastly safeguard public skin health through innovation.About VitiligoVitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. The discolored areas usually get bigger with time and the condition could influence skin on any part of the patients’ body. Vitiligo usually affects the appearance of patients, especially on exposed areas such as the face and neck. According to a study that involved over 1,000 diagnosed vitiligo patients, over 45% of patients have facial involvement, and over 20% of patients have neck involvement[1].The obvious presence of white patches may make patients feel that their appearance has been compromised, which in turn materially affects their social life, and is associated with a significantly higher incidence of mental health disorders; accordingly, there is an urgent need for effective treatment options for vitiligo[2].It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[1]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. Ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance.More Information About Ruxolitinib Phosphate CreamRuxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is the first and only drug approved for the repigmentation of non-segmental vitiligo by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)[3,4]. In the U.S., the Product is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised adult and pediatric patients aged 2 years and older whose disease is not well controlled with topical prescription therapies, or when those therapies are not advisable. In Europe, ruxolitinib phosphate cream is approved for the topical treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. In China, besides vitiligo indication, the product’s NDA for the treatment of mild-to-moderate AD in adults and pediatric patients aged 2 years and older is also under regulatory review, which has been included in the Priority Review List and is expected to accelerate the Product’s AD review process for marketing approval.The Group, through the subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream (excluding territories in which exclusive rights have already been licensed), marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. China Insights Consultancy’s industrial report 2. Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis[J]. Journal of the European Academy of Dermatology and Venereology, 2018,32(8):1343-1351. DOI:10.1111/jdv.14739. 3. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream4. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurarCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2026年3月13日 - (亞太商訊 via SeaPRwire.com) - 2026年3月12日，康哲藥業控股有限公司 （「康哲藥業」）欣然宣佈，旗下德鎂醫藥有限公司（「德鎂醫藥」，專業聚焦皮膚健康的創新型醫藥企業，正申請於香港聯合交易所有限公司主板獨立上市），其創新處方藥磷酸蘆可替尼乳膏（百盧妥(R)）（「產品」，在美國、歐洲及加拿大以Opzelura(R)的名稱銷售）在全國30個省級行政區為白癜風患者開出首批處方，覆蓋包括復旦大學附屬華山醫院、上海市皮膚病醫院、南方醫科大學皮膚病醫院、成都市第二人民醫院、吉林大學白求恩第一醫院、中南大學湘雅二醫院、和睦家醫療集團等千家在皮膚健康及疾病管理領域具有影響力的公立及私立醫療機構*，並實現超1,300家線下藥店以及京東電商平臺同步可及。*醫院排名不分先後磷酸蘆可替尼乳膏為中國批准的首款用於白癜風治療的外用JAK抑制劑，今日正式拉開產品規模化臨床應用的序幕，標誌著我國白癜風治療領域實現突破性進展，邁入精准靶向治療的全新時代，產品將以經過臨床充分驗證的安全和有效性，點亮千萬白癜風患者複色希望。磷酸蘆可替尼乳膏的跨越式商業化進程，不僅彰顯了康哲藥業卓越的產品運營能力，更充分體現了國家藥政改革對臨床亟需創新藥加速可及的有力支持。受益於海南自貿港醫療健康產業整合性優勢，以及 「臨床急需進口」 政策，2023年8月，產品率先在海南博鼇樂城國際醫療旅遊先行區博鼇超級醫院啟動臨床應用，隨後試點應用逐步擴展至粵港澳大灣區、京津等區域指定醫療機構。在我國藥品真實世界數據應用試點有關程序，以及海南省藥品監督管理局與海南博鼇樂城國際醫療旅遊先行區管理局的支持下，產品通過「先行先試」臨床應用積累中國真實環境的診療數據，大大提速產品臨床、註冊和獲批上市進程，並成功於2026年1月30日取得《藥品註冊證書》（批准日期2026年1月27日）。獲批以來，僅耗時不到1.5個月（含春節假期），磷酸蘆可替尼乳膏便實現全國多地、多醫院首批處方集中落地，這亦是康哲藥業各部門、相關監管部門及合作夥伴高效聯動、共同努力的成果。在北京大興臨空區聯合管委會跨部門合作機制的有力保障下，產品具備進口條件後24小時內即完成了藥品通關審批、藥品抽樣及海關程序，並於7個工作日內取得藥品檢驗報告，全程跑出了高效務實的「中國創新藥加速度」。在此過程中，北京市藥監局主動開展商業規模批次政策的全流程指導，政務中心高效完成通關備案；北京市藥品檢驗研究院則通過前置方法學預檢驗、開闢創新藥專項通道，並在春節期間持續作業，全力確保檢驗進度高效推進；大興機場海關則提前對藥品申報要素進行專項指導，快速完成報關審核和藥品放行工作。各方協同、流程並聯，合力為磷酸蘆可替尼乳膏上市按下「快進鍵」，助力該臨床急需創新藥惠及廣大患者。隨著產品進入規模化臨床應用階段，將進一步強化德鎂醫藥皮膚疾病綜合解決方案及品牌價值。德鎂醫藥依託在皮膚健康領域的領先地位，將持續推進磷酸蘆可替尼乳膏使更多白癜風患者獲益，以創新之力堅定守護民眾皮膚健康。關於白癜風白癜風是一種慢性自身免疫性疾病，其特徵是皮膚色素脫失，其發病原因為產生色素的細胞即黑素細胞的缺失。脫色區域通常會隨著時間的推移而擴大，且該病症可能影響患者身體任何部位的皮膚，影響患者的容貌，尤其是面部、頸部等顯眼部位。根據一項對1,000多名已確診白癜風患者進行的研究，超過45%的患者面部受累，超過20%的患者頸部受累[1]。白色斑塊的明顯存在可能會讓患者認為自身的形象受到損害，進而嚴重影響其社會活動，精神疾病發病率顯著增加，因此白癜風的治療需求非常迫切[2]。據估算，中國約有1,030萬人患有白癜風，其中約820萬人患有非節段型白癜風[1]。現有療法，如外用糖皮質激素（TCS）及外用鈣調神經磷酸酶抑制劑（TCIs）存在臨床缺陷，長期用藥有不良反應或療效有限。磷酸蘆可替尼乳膏成功填補了白癜風靶向藥物治療的空白，具有重大標誌性意義。關於磷酸蘆可替尼乳膏的更多資訊磷酸蘆可替尼乳膏（Opzelura(R)）是Incyte開發的選擇性JAK1/JAK2抑制劑蘆可替尼製成的一種創新型乳膏，是經美國食品藥品監督管理局（FDA）及歐洲藥品管理局（EMA）批准的首款也是唯一一款用於非節段型白癜風複色的藥物[3,4]。在美國，產品獲批用於局部治療成人及12歲及以上兒童患者的非節段型白癜風；及其他外用藥控制不佳或不建議使用時，非免疫功能受損的2歲及以上兒童和成人輕中度特應性皮炎的局部短期和非持續性慢性治療。在歐洲，磷酸蘆可替尼乳膏被批准用於局部治療成人及12歲及以上青少年伴面部受累的非節段型白癜風。在中國，除白癜風適應症外，產品2歲及以上兒童和成人輕中度特應性皮炎（AD）適應症亦處於NDA審評階段， 且該項NDA已獲納入優先審評品種名單，有望加快產品AD適應症上市審評進程。康哲藥業於2022年12月2日，通過德鎂醫藥的附屬公司與Incyte就磷酸蘆可替尼乳膏訂立合作和許可協議（「許可協議」），獲得在中國大陸、香港特別行政區、澳門特別行政區、臺灣地區及東南亞十一國（「區域」）研發、註冊及商業化產品的獨家許可權利，以及在區域內生產產品的非獨家許可權利。德鎂醫藥的附屬公司已將磷酸蘆可替尼乳膏除中國大陸外的其他區域的相關權利再許可予康哲藥業（不包括德鎂醫藥及其附屬公司）。Incyte擁有磷酸蘆可替尼乳膏全球開發和商業化權利（已獨佔許可區域除外），在美國及歐洲以Opzelura(R)的名稱銷售。Opzelura(R)和Opzelura(R)標識是Incyte的註冊商標。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化，把控產品全生命週期管理的開放式平臺型企業，致力於提供有競爭力的產品和服務，滿足尚未滿足的醫療需求。康哲藥業專注於全球首創（FIC）及同類最優（BIC）的創新產品，並高效推進創新產品臨床研究開發和商業化進程，賦能科研成果向診療實踐的持續轉化，造福患者。康哲藥業聚焦專科領域，擁有被驗證的商業化能力，廣泛的渠道覆蓋和多疾病領域專家資源，核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展，以鞏固心腎代謝/消化/眼科/皮膚健康業務競爭力，帶來專科規模效率，其中皮膚健康業務（德鎂醫藥）已成為其細分領域的龍頭企業，並擬於聯交所獨立上市。同時，康哲藥業持續推動研產銷全產業鏈在東南亞及中東區域運營發展，以獲取新興市場的增量，助力集團實現高質量可持續發展。參考文獻/資料1.數據來自灼識諮詢報告2.Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis[J]. Journal of the European Academy of Dermatology and Venereology, 2018,32(8):1343-1351. DOI:10.1111/jdv.14739.3.FDA批准信息可在Incyte官網查詢，網址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream4.EMA批准信息可在Incyte官網查詢，網址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣，非廣告用途。本新聞不對任何藥品和-醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療資訊，請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請，不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制，但康哲藥業並無進行任何說明或保證、明述或暗示，或其他表述，對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述，該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證，存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測，康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) – 12 March 2026, Guoquan Food (Shanghai) Co., Ltd. ("Guoquan" or the "Company"; stock code: 2517.HK), a leading one-stop home meal products brand in China, announced its annual results for the year ended 31 December 2025, which have been reviewed by the Audit Committee of the Board.Adhering to the strategic positioning of "community central kitchen" in 2025, the Company successfully established a holistic instant retail store network through a multi-channel, multi-scenario omni-channel layout and the deep integration of online and offline operating models. The Company continuously delved into consumers' demand, developed and iterated a diverse suite of product portfolios, deepened refined store operation and management, and strengthened the construction of a membership ecosystem, effectively enhancing store operational efficiency and market competitiveness. Concurrently, the Company continued to deepen its industrial layout and promote the integrated closed-loop construction of "production, supply and marketing", achieving stable development throughout the year.For the year ended 31 December 2025, the Company's revenue amounted to RMB7,810.0 million, representing a year-on-year increase of 20.7%. Gross profit reached RMB1,686.6 million, a year-on-year increase of 19.0%. Net profit was RMB453.9 million, a significant year-on-year increase of 88.2%. Core operating profit (adjusted for non-recurring items such as gains or losses on fair value changes on unlisted convertible redeemable preferred shares and donations for fire rescue in Tai Po, Hong Kong) was RMB460.7 million, representing a year-on-year increase of 48.2%. Basic and diluted earnings per share were RMB0.1630, a substantial year-on-year increase of 93.8%.Continuously Strengthening Omni-channel Instant Retail: Offline Expansion and Online Engagement Drive GrowthAs of 31 December 2025, the Company's total number of stores nationwide reached 11,566, a net increase of 1,416 stores from 10,150 as at the end of 2024, covering 31 provinces, autonomous regions and municipalities. In terms of regional store layout, the Company achieved a net increase of 1,004 township-level stores in 2025. Addressing the consumption characteristics and needs of township markets, the Company developed differentiated product structures and store displays, accurately aligning with consumer demands in lower-tier markets and further enhancing township market penetration. Concurrently, the Company continued to deploy smart retail scenarios in mid-to-high-tier markets, completing the intelligent and unmanned transformation and upgrade of over 3,000 retail stores in 2025, achieving synergistic development between lower-tier and mid-to-high-tier markets.To empower franchisees, facilitate their sales growth, and further expand consumer reach while offering a more flexible shopping experience, the Company continuously provides support and guidance to franchisees in core areas such as store operations and business development. Leveraging the Company's Guoquan APP, WeChat mini-program, third-party food delivery platforms and social commerce platforms (such as Douyin), a multi-level online sales network has been established. In 2025, the Company achieved over 9.41 billion impressions on platforms through its multi-level Douyin accounts matrix. Stores generated GMV of RMB1.49 billion via the Douyin channel, representing a year-on-year increase of 75.3%.Membership Ecosystem Continuously Improved; Product Portfolio Enhances in Scenarization and RichnessIn 2025, the operation of the Guoquan membership program yielded significant results, further releasing the value of the membership ecosystem. During the Reporting Period, the number of the Company's registered members reached approximately 64.9 million, a year-on-year increase of 57.1%, demonstrating rapid expansion of the membership base. The prepaid card business also achieved stable growth, with the value stored in prepaid cards amounting to approximately RMB1.2 billion during the Reporting Period, a year-on-year increase of 22.3%. This indicates continuously improving member stickiness and consumption contribution, forging a closer connection with consumers.Relying on its substantial membership base, the Company persistently pursues innovation in its product offerings, consistently upholding the business philosophy of providing consumers with "tasty, convenient and value-for-money" products. It continuously enriches its product portfolio and iterates new products to comprehensively meet consumers' diverse dining needs. As of 31 December 2025, the Company had introduced 282 new SKUs of hot pot and barbecue products. It created multiple scenarized meal suites such as the "Barbecue Camping Container Set", "Crayfish Feast Set", and "Six Popular Hot Pot Sets", achieving deep integration of products and consumption scenarios. Furthermore, the Company expanded its product categories within the drinks and beverage consumption scenario, launching products such as NFC fruit juices, craft beer, and flavored tea beverages. This continuously enhances the richness and diversification of the product matrix, further perfecting the one-stop meal products supply system.Deepening Industrial Layout; Strengthening Digitalized Supply Chain ControlGuoquan continues to promote the integrated closed-loop construction of "production, supply and marketing". Adopting a "one-product-one-factory" strategy, it further deepens the breadth and depth of its industrial layout, providing solid production capacity support for business development. As of 31 December 2025, the Company possessed seven food ingredient production plants, covering core categories such as condiments, meatballs, paste and aquatic products, and beef products, forming a comprehensive and well-defined production capacity matrix. Concurrently, the construction of the Company's food production base in Danzhou, Hainan Province, officially commenced. This base will further expand its geographical coverage, optimize the supply chain's radiation radius, and strengthen the national production capacity layout and logistics reach.This solid industrial foundation continuously improves the operational efficiency of the digitalized supply chain. Based on the supply chain system operating from factory to central warehouse and to retail stores, the Company can monitor supply and demand dynamics from the procurement end to the store end, and closely manage inventory levels, thereby achieving efficient management of the entire supply chain. As of 31 December 2025, the Company had deployed 20 digitalized central warehouses across China, achieving swift product circulation through digital stock and barcode management. Simultaneously, the digitalization of the supply chain covering core segments such as production, procurement, warehousing, and logistics allows for precise monitoring of supply-demand dynamics and inventory levels, ensuring the timely supply of products to stores in the Chinese mainland. This comprehensively enhances the overall operational efficiency of the supply chain, solidifying core barriers in cost control and quality assurance.Six Core Strategic Directions: Continuously Advancing Business UpgradesIn 2026, Guoquan targets that the total number of stores will exceed 14,500, representing a net increase of over 2,934 stores, with an estimated store closure rate of less than 4%. It targets high-single-digit growth in store efficiency, and the number of registered members is targeted to exceed 95 million. The Company targets that the growth rate of core operating profit will be significantly higher than that of its revenue.First, Fully expand the sales network with four stores jointly advancing with concerted efforts. Guoquan will continue to build a multi-level sales network, accelerate the expansion of large stores in townships, practice the philosophy of "food equality", and precisely meet the consumption needs of residents in county and township markets. Concurrently, it will explore innovative store formats and upgrade the franchisee management system to build a symbiotic and mutually beneficial franchise ecosystem.Second, Deepen the strategy of community central kitchen to expand community consumption scenarios. The Company will focus on creating food retail solutions for "four meals a day", continuously diversifying its product categories and building a more competitive product matrix to achieve organic sales growth while further consolidating its advantages in lower-tier market layout.Third, Deepen membership operation and IP to advance the community brand project. The Company will continue to advance refined membership operation, deeply integrate media resources such as popular TV commercials, offline community advertising and social media and e-commerce platforms (such as Douyin) to expand its membership base, and improve the membership rights system to enhance member loyalty and stickiness. Furthermore, it will further deepen the operation of its brand IP image "Guobao" to strengthen brand value and emotional resonance with consumers.Fourth, AI big data empower stores to innovate smart retail scenarios. By integrating Internet of Things, big data, and AI technology, the Company will drive the smart operation of stores with data. It will promote the in-depth integration of the Guoquan stir-fry business format with smart cooking machines, accurately analyze consumers' dining habits, optimize dish parameters and cooking procedures for smart cooking machines, realize the standardized production of stir-fry dishes, and optimize the consumer experience.Fifth, Continue to promote the industrial layout and strengthen the advantage of one-product-one-factory. Adhering to the "one-product-one-factory" strategy, Guoquan will further integrate upstream resources domestically and internationally, accelerate the construction of the food production base in Danzhou, Hainan Province, increase R&D investment, and launch more product portfolios with a high quality-price ratio.Sixth, Develop overseas markets in phases to deliver the good taste of China. Guoquan plans to explore and establish a presence in overseas regional markets in a phased manner to unlock long-term growth potential. Leveraging its core competitiveness, it will steadily advance its overseas market exploration. It also plans to take the lead in opening stores in Hong Kong Special Administrative Region, China to accumulate and gather operational experience, gradually achieving overseas product sales and enhancing global brand visibility.About Guoquan Food (Shanghai) CO., LTD. (2517.HK):Guoquan Food (Shanghai) Co., Ltd. (“Guoquan”; Stock Code: 2517.HK) is the leading one-stop home meal products brand in China, offering a variety of ready-to-eat, ready-to-heat, ready-to-cook and prepared ingredients, with a focus on at-home hotpot and barbecue products.  Leveraging Company’s robust supply chain capabilities, a strategic industrial layout with self-owned factories, a nationwide network of around 10,000 instant retail stores, and a carefully curated product portfolio, Company offer a variety of home meal products solution under the “Guoquan Shihui” brand, catering to different dining scenarios.This press release is issued by EverBloom (HK) Communications Consultants Group Limited on behalf of Guoquan Food (Shanghai) Co., Ltd. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

From a joyful Raya musical to new and improved festive recipes, Spritzer Sparkling inspires Malaysians to embrace fresh new ideas alongside tradition to elevate their Raya celebrationsSpritzer Sparkling’s 2026 Raya musical brand film “Samting-Samting”, stars Fimie Don and Wani Kayrie as a married couple, and Elliza Razak as Mak Ngah.TAIPING, Malaysia, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) - Hari Raya Aidilfitri in the month of Syawal is a cherished time of celebration and time-honoured family traditions, with the kitchen often becoming the heart of the festivities. As families balik kampung and fill their homes with the joy and warmth of festive cooking this year, Spritzer Sparkling invites Malaysians to celebrate Raya with a modern twist through its ‘Serikan Raya, Sparkling-kan Suasana’ campaign, showcasing the versatility of the product in boosting the creativity and flair of beloved Raya dishes.For the first time, Spritzer Sparkling is expanding beyond its well-loved role as a beverage mixer with a fresh take on festive cooking through the multipurpose use of its naturally refreshing sparkling water in your favourite recipes. Spritzer Sparkling transforms five traditional must-have Raya dishes into festive showstoppers, bringing a new dimension of taste with its lively carbonation enhancing the texture, crispiness, and tenderness of the dishes. These favourites include Cucur Udang Crispy, Rendang Tok Melting, and Roti Jala with Kari Ayam, alongside refreshing drinks like Bunga Longan Sparkling and Limau Selasih Pudina Sparkling.This Raya, add a little ‘Samting-Samting’ extra to your recipes for an exciting new twist on your favourite festive dishes with Spritzer SparklingEach recipe showcases how the natural bubbles from Spritzer Sparkling help create lighter, crispier batters for a satisfying crunch and more tender, flavourful meats without changing the essence of the dishes. Whether it is giving your cucur udang a delightful crisp or tenderising your rendang meat and shortening the braising time, Spritzer Sparkling makes these traditional favourites even more enjoyable in simple, effortless ways.Shiao Chan, Head of Marketing at Spritzer, said, “Hari Raya Aidilfitri is a celebration deeply rooted in family traditions where food plays a central role in bringing people together. Through ‘Serikan Raya, Sparkling-kan Suasana’, we wanted to show Malaysians that tradition and heritage can co-exist and even be preserved through innovation and new perspectives. Spritzer Sparkling is not just a refreshing beverage for every season, but also a multi-faceted ingredient that can enhance festive dishes and drinks, creating memorable family moments in the kitchen and around the dining table.”A Musical Aidilfitri AwaitsBringing the Raya story to life is Spritzer’s musical film titled ‘Samting-Samting’, starring Fimie Don, Wani Kayrie and Elliza Razak. As the official Spritzer Sparkling brand ambassadors for Raya 2026, Fimie Don and Wani Kayrie, play a modern newlywed couple returning to the husband’s kampung for their first Raya together in the film that blends comedy, drama and music in an irresistibly Malaysian narrative.The young wife, Alia, takes on the kitchen with confidence, using her own modern approach to classic family dishes, prepared using her secret ingredient: Spritzer Sparkling. Mak Ngah, the family’s long-standing culinary matriarch, feels her role is being challenged and grows increasingly suspicious about Alia’s unusually delicious cooking, suspecting “Samting-Samting” is amiss. The story humorously unravels the “secret” behind Alia’s crowd-pleasing flavours, capturing family dynamics and celebrating new perspectives, shared discovery, and the warmth of intergenerational bonding.Home-cooks excited to try this new twist to classic recipes can check out the recipes for the featured dishes and beverages using Spritzer Sparkling as a game-changing ingredient on Spritzer’s Raya microsite here.Spritzer’s 2026 Raya campaign celebrates family traditions, playful generational dynamics in the kitchen, and creative festive cooking with Spritzer Sparkling.Also available on the website are the musical film, promotional details, meet-and-greet information with Fimie Don and Wani Kayrie, as well as gift-with-purchase promotions available at participating outlets nationwide.About SpritzerEstablished in 1989, Spritzer is a leading Malaysian bottled water brand, sourcing natural mineral water from a protected 430-acre rainforest in Taiping. Naturally filtered through underground rock layers for over 15 years, our water is enriched with essential minerals like Silica, known to support skin, bones, hair, and nails.Combining smart manufacturing with sustainable practices, Spritzer ensures every bottle meets the highest quality and safety standards. Our packaging is 100% recyclable and made from recycled materials, reflecting our commitment to environmental stewardship and a circular economy.Tested annually by SIRIM to be free from microplastics, Spritzer offers consumers trusted, natural hydration. Our diverse product range includes Natural Mineral Water, Original and Flavoured Sparkling Water, Distilled Water, and Fruit-Flavoured Beverages—crafted to suit every lifestyle and occasion.With a clear vision to become a fully circular brand by 2030, Spritzer leads the industry in innovation, quality, and sustainability.Spritzer — where nature, innovation, and sustainability come together in every bottleFor more information, visit www.spritzer.com.myFor media inquiries please contact:Farah ShahrulAssociate Consultant, Narro CommunicationsE: farah@narrocomms.comWinnie ChinHead of Public Relations, Spritzer BhdE: winniecgl@spritzer.com.my        Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月13日 - (亞太商訊 via SeaPRwire.com) - 3月12日，中國領先的一站式在家吃飯餐食產品品牌鍋圈食品（上海）股份有限公司（簡稱「鍋圈」或「公司」，股票代號：2517.HK）公佈截至2025年12月31日止十二個月經董事會審核委員會審閱之全年業績。2025年，鍋圈堅持「社區央廚」的戰略定位，通過多渠道、多場景的全域佈局，深度融合線上線下運營模式，成功構建全方位的即時零售門店網路。公司持續深耕消費者需求，不斷開發並迭代多樣化套餐產品組合，深化門店精細化運營管理，健全會員生態體系建設，有效提升了門店經營效能與市場競爭力。與此同時，公司持續深化產業端佈局，推動「產供銷」一體化閉環建設，實現全年穩健發展。截至2025年12月31日止年度，鍋圈收入為人民幣7,810.0百萬元，同比增長20.7%；毛利為人民幣1,686.6百萬元，同比增長19.0%；淨利潤為人民幣453.9百萬元，同比增長88.2%；核心經營利潤（經調整後非上市可轉換可贖回優先股公允價值變動損益、香港大埔火災救援捐贈等一次性因素後）為人民幣460.7百萬元，同比增長48.2%；每股基本及攤薄盈利為人民幣0.1630元，同比增長93.8%。持續夯實全渠道即時零售 線下擴張+線上聯動驅動增長截至2025年12月31日，鍋圈全國門店總數達11,566家，較2024年末的10,150家淨增1,416家，全面覆蓋全國31個省、自治區及直轄市。在門店區域佈局上，2025年公司淨新增1,004家鄉鎮門店，並針對鄉鎮市場消費特點與需求，打造差異化產品結構與門店陳列，實現與下沉市場消費需求的精准匹配，進一步提升鄉鎮市場滲透率。與此同時，公司持續佈局中高線市場智慧化零售場景，2025年完成超三千家零售門店的智慧化、無人化改造升級，實現下沉市場與中高線市場的協同發展。為賦能加盟商、促進其銷售增長，並進一步擴大消費者覆蓋範圍、提供更靈活的購物體驗，公司持續在門店運營、業務發展等核心環節為加盟商提供支持，依托鍋圈APP、微信小程序、第三方外賣平台及社交商務平台（如抖音），構建多層次的線上銷售網絡。2025年，公司通過多層級抖音賬號矩陣實現超94.1億次平台曝光量，門店通過抖音渠道實現GMV達14.9億元，同比增長75.3%。會員生態體系持續完善 產品矩陣場景化與豐富度雙提升2025年，鍋圈會員計劃運營成效顯著，會員生態體系價值進一步釋放。於報告期內，公司註冊會員數量達約6,490萬名，同比增長57.1%，會員規模實現快速擴張；預付卡業務同步實現穩健增長，報告期內預付卡預存金額達約人民幣12.0億元，同比上升22.3%，會員黏性與消費貢獻持續提升，與消費者的連結更為緊密。以龐大的會員基礎為依托，公司持續深耕產品端創新，始終秉持「好吃方便還不貴」的經營理念，不斷豐富產品組合並迭代新品，全方位滿足消費者多樣化用餐需求。截至2025年12月31日，公司共推出282個火鍋及燒烤類產品的新SKU，打造「燒烤露營集裝箱套餐」「小龍蝦暢享套餐」「六大國民火鍋套餐」等多款場景化套餐產品，實現產品與消費場景的深度融合。此外，公司圍繞酒水飲料消費場景進行品類拓展，推出NFC果汁、精釀啤酒、風味茶飲等產品，持續提升產品矩陣的豐富度與多元化程度，進一步完善一站式餐食產品供給體系。深化產業端佈局 強化供應鏈數字化管控鍋圈持續推動「產供銷」一體化閉環建設，通過「單品單廠」策略進一步深化產業端佈局的深度與廣度，為業務發展提供堅實的產能支撐。截至2025年12月31日，公司已擁有7個食材生產廠，覆蓋調味料、丸滑水產、牛肉等核心品類，形成品類齊全、分工明確的產能矩陣；與此同時，公司位於海南省儋州市的食品生產基地正式動工建設，未來將進一步拓寬地理覆蓋範圍，優化供應鏈輻射半徑，強化全國產能佈局與物流輻射能力。產業端的堅實基礎推動供應鏈數字化運營效率持續提升，基於從工廠到中央倉再到零售門店的供應鏈體系，公司能對從採購端到門店端的供需動態進行監控，並密切把控存貨水準，從而實現對整個供應鏈的高效管理。截至2025年12月31日，公司已佈局20個數字化中央倉庫，透過數字化存貨和條碼管理實現產品快速流通；與此同時，實現生產、採購、倉儲、物流等核心環節的供應鏈數字化，精準監控供需動態與存貨水平，保障中國內地門店產品及時供應，全面提升供應鏈整體運營效率，築牢成本管控與品質把控的核心壁壘。六大核心戰略方向 持續推進業務升級2026年，鍋圈預計門店總數超過14,500家，即淨新增門店超2,934家，預計關店率低於4%，門店店效實現高單位數增長，註冊會員數量超過95百萬名。公司預計核心經營利潤增速將明顯高於收入增速。一是，全面拓展銷售網路，四店齊發聚力共進。鍋圈將繼續打造多層級銷售網絡，加速鄉鎮大店拓展步伐，踐行「美食平權」理念，精準對接縣鄉市場居民的消費需求；與此同時，探索創新店型且升級加盟商管理體系，構建共生共贏的加盟生態。二是，深化社區央廚戰略，延展社區消費場景。公司將圍繞「一日四餐」打造餐飲零售解決方案，持續佈局多元品類，打造更具市場競爭力的產品矩陣，實現銷售規模的有機增長的同時，進一步夯實下沉市場佈局優勢。三是，深耕會員運營及IP，推進社區品牌工程。公司將持續推進會員精細化運營，深度整合知名電視廣告、線下社區廣告和社交電商平台（如抖音）等媒體資源，擴大會員規模，並完善會員權益體系，提升會員忠誠度與黏性。與此同時，公司將進一步深化品牌IP形象「鍋寶」的運營，提升品牌價值與消費者的情感連結。四是，AI大數據賦能門店，創新智慧零售場景。結合物聯網、大數據及AI技術實現門店智慧化運營，推動鍋圈小炒與智慧炒菜機深度融合，精準分析消費者餐飲習慣，優化智慧炒菜機的菜品參數與烹飪流程，實現菜品標準化製作並優化消費體驗。五是，持續推動產業佈局，強化單品單廠優勢。鍋圈堅守「單品單廠」策略，將進一步整合海內外上游資源，加快海南省儋州市食品生產基地建設，加大研發投入並推出更多高性價比產品組合。六是，海外市場分階落地，傳遞中國好味道。鍋圈計劃分階段佈局海外市場，挖掘長期增長潛力，立足核心競爭力穩步推進海外市場探索，亦計劃率先在中國香港開設門店並積累運營經驗，逐步實現產品海外銷售，提升全球品牌知名度。關於鍋圈食品（上海）股份有限公司(2517.HK)：鍋圈食品（上海）股份有限公司（股票代號：2517.HK）是中國領先的一站式在家吃飯餐食產品品牌，提供即食、即熱、即煮和即配食材，並專注於在家火鍋和燒烤產品。憑藉強大的供應鏈能力、自有工廠的產業端佈局，遍佈全國的萬家即时零售門店網絡及精心策劃的產品組合，公司使用「鍋圈食匯」品牌為消費者提供各種在家吃飯餐食產品解决方案，服務於不同的用餐場景。本新聞稿由九富（香港）財訊公關集團有限公司代表鍋圈發佈。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - March 12, 2026) - Founders Metals Inc. (TSXV: FDR) (OTCQX: FDMIF) (FSE: 9DL0) ("Founders" or the "Company") announces that Lower Antino has been upgraded from Intermediate to Advanced Target status - the same internal classification* as Upper Antino - at its Antino Gold Project in southeastern Suriname (Figure 1). The upgrade follows cumulative drilling of 50 diamond drill holes including eight new holes reported here that continue to demonstrate broad, continuous gold mineralization, highlighted by 65.9 metres (m) of 1.16 grams per tonne (g/t) gold (Au) within a broader envelope of 115.0 m of 0.83 g/t Au from surface in drill hole LA046.HighlightsLower Antino upgraded to Advanced Target status with 50 drill holes released to date with an additional 10 holes pending assays and further expansion drilling underwayBest intercept to date: 65.9 m of 1.16 g/t Au within 115.0 m of 0.83 g/t Au from surface (LA046)Broad mineralized envelopes confirmed: 113.5 m of 0.34 g/t Au from surface including 30.0 m of 0.82 g/t Au (LA044)Intrusion-hosted gold mineralization intersected in all eight drill holes reported in this release; mineralization remains open along strike and at depthColin Padget, President & CEO, commented, "Lower Antino's upgrade from Intermediate to an Advanced Target - now sharing the same classification as Upper Antino - reflects consistent, broad gold mineralization across a growing number of drill holes. LA046 returning 65.9 metres of 1.16 g/t gold within a 115-metre mineralized envelope is the best intercept to date at this target and underscores the scale and continuity of the Lower Antino intrusion-hosted gold system. With gold in every hole and consistently wide intercepts, Lower Antino is emerging as a meaningful contributor to the district's overall potential. While our focus remains on exploration and expansion drilling, Lower Antino's advancement to the same classification as Upper Antino means it is expected to be considered for inclusion in any future resource estimate for the district."Lower Antino - Upgraded to Advanced TargetThe Company reports assay results from eight diamond drill holes (LA043 to LA050) at the Lower Antino target, located approximately 3.5 km east of the Upper Antino deposit (Figure 1). All eight holes intersected gold mineralization, with results highlighted by 65.9 m of 1.16 g/t Au within 115.0 m of 0.83 g/t Au in LA046 (Table 1). The 115-metre intercept in LA046 begins at surface and represents an up-dip expansion of the previously released 90.0 m of 1.02 g/t Au in LA041, confirming the continuity and growth potential of the mineralized zone.Based on cumulative drilling results, Founders has upgraded Lower Antino from Intermediate Target to Advanced Target status, ranking it on the same tier as Upper Antino in terms of overall target quality and scale potential. The upgrade reflects the demonstrated continuity of gold mineralization across numerous drill sections and identification of multiple parallel, northeast-trending mineralized zones over approximately 1.9 km of drill-defined strike length within a broader 1.5 km by 2.8 km gold-in-auger anomaly.The target is open along strike and at depth with drilling ongoing to the south and southeast at regular 100 to 200 metre steps. Overall, gold mineralization remains consistent with previous Lower Antino drill results and is hosted in intensely sericite-altered, sheared tonalite with disseminated pyrite and quartz-pyrite veining. The southernmost hole in this release (LA050), intersected 24.0 m of 0.57 g/t Au and represents approximately 200 metres of southward expansion of the mineralized system. Assay results are presented in Table 1, with drill hole locations in Table 2.Lower Antino is one of two Advanced Targets within Founders' 102,360-hectare contiguous land package, which hosts eight drill tested gold targets across the 55 km long Antino concession. The upgrade of Lower Antino adds meaningful scale to the Company's growing inventory of drill-defined gold mineralization at the district level. The Company will continue to systematically advance and upgrade high-quality targets as defined by geological criteria linked to scale and growth potential.*The Company's internal target classification system reflects drill density, demonstrated continuity of mineralization, and data sufficiency; it does not correspond to NI 43-101 resource categories.Figure 1: Antino Gold Project Property MapTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/7574/288304_571962fb64ca9a3d_001full.jpgFigure 2: Lower Antino Plan MapTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/7574/288304_571962fb64ca9a3d_002full.jpgFigure 3: Lower Antino cross-section through central gold trend.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/7574/288304_571962fb64ca9a3d_003full.jpgTable 1: Lower Antino Drill ResultsDrillholeFrom (m)To (m)Interval (m)Au (g/t)Results from This ReleaseLA043162.00174.0012.001.56incl.167.00174.007.002.56LA0441.50115.00113.500.34incl.8.1038.1030.000.82LA0450.0020.1020.100.31and111.00124.0013.000.44LA0460.00115.00115.000.83incl.41.10107.0065.901.16LA0470.008.108.100.94and149.00156.007.000.46LA0480.0027.6027.600.22and173.00178.005.000.80LA0496.6011.104.500.21LA05047.1071.1024.000.57Previously Released Highlight ResultsLA041156.00246.0090.001.02incl.176.00178.002.0028.44LA00374.10156.0081.901.00incl.106.00132.0026.002.36LA0250.00241.00241.000.27incl.0.0086.1086.100.43LA03329.1060.0030.901.56LA02472.00122.0050.001.02LA028108.00163.0055.000.64incl.110.00117.007.002.32LA0190.0065.0065.000.49incl.44.1065.0020.901.11LA01033.6057.6024.001.23 **Intervals are down-hole depths. True widths of mineralization are estimated to be approximately 85% of the down-hole interval based on currently available results and observations. All are diamond drill holes. Average grades are calculated with un-capped gold assays, as insufficient drilling has been completed to determine capping levels for higher grade gold intercepts. Composites are calculated using a 0.10 g/t Au cut-off grade with <5.0 m of internal dilution of zero grade and a minimum composite length of 2.0 m. <0.2 g/t Au intercept are not included.Table 2: Lower Antino Drill Hole Locations from This ReleaseDrillholeEasting (m)Northing (m)Elevation (m)Azimuth (°)Dip (°)Depth (m)LA043821605.33401160.67176.46269.80-50.20212.14LA044821488.00401166.00177.47270.20-50.10206.00LA045821484.00401462.00125.22270.20-50.20302.00LA046821456.00401365.00152.33270.00-50.00200.14LA047821535.00401794.67127.95270.10-50.20263.11LA048821510.00401683.00147.21269.80-50.40287.00LA049821606.67401064.33174.81270.20-50.20320.00LA050821494.33401065.67176.94270.20-50.10212.00 *The coordinate reference system is WGS 84, UTM zone 21N (EPSG 32621)About Founders Metals Inc.Founders Metals Inc. is a Canadian gold exploration company building a district-scale gold camp in southeastern Suriname. The Company controls a 102,360-hectare contiguous land package in the Guiana Shield - the largest uninterrupted package of highly prospective greenstone belt geology in the region. Founders is backed by strategic partnerships with Gold Fields and B2Gold and is executing one of the most active exploration programs in the global junior gold sector. The Company is committed to responsible exploration, strong community engagement, and disciplined capital allocation as it advances Suriname's next major gold camp.ON BEHALF OF THE BOARD OF DIRECTORS,Per: "Colin Padget"Colin PadgetPresident, Chief Executive Officer, and DirectorContact InformationKatie MacKenzie, Vice President, Corporate DevelopmentTel: +1 306 537 8903 | katiem@fdrmetals.comCautionary Statement Regarding Forward-Looking InformationThis press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation, including statements regarding long term value creation and the Company's prospects. Forward-looking information can generally be identified by words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes", or variations indicating that certain actions, events or results "may", "could", "would", "might" or "will" occur or be achieved.Forward-looking statements are based on management's current expectations and reasonable assumptions but are subject to business, market, and economic risks, uncertainties, and contingencies that may cause actual results to differ materially from those expressed or implied, including: general business and economic uncertainties; exploration results; mining industry risks; and other factors described in the Company's most recent annual management discussion and analysis. Although the Company has attempted to identify important factors that could cause actual results to differ materially, other factors may cause results not to be as anticipated. There can be no assurance that forward-looking information will prove accurate, as actual results and future events could differ materially from those anticipated. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information except in accordance with applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.All material information on Founders Metals can be found at www.sedarplus.ca.Quality Assurance and ControlSamples were analyzed at FILAB Suriname, a Bureau Veritas Certified Laboratory in Paramaribo, Suriname (a commercial certified laboratory under ISO 9001:2015). Samples are crushed to 75% passing 2.35 mm screen, riffle split (700 g) and pulverized to 85% passing 88 µm. Samples were analyzed using a 50 g fire assay (50 g aliquot) with an Atomic Absorption (AA) finish. For samples that return assay values over 5.0 grams per tonne (g/t), another cut was taken from the original pulp and fire assayed with a gravimetric finish. Founders Metals inserts blanks and certified reference standards in the sample sequence for quality control. External QA-QC checks are performed at ALS Global Laboratories (Geochemistry Division) in Lima, Peru (an ISO/IEC 17025:2017 accredited facility). A secure chain of custody is maintained in transporting and storing of all samples. Drill intervals with visible gold are assayed using metallic screening. Rock chip samples from outcrop/bedrock are selective by nature and may not be representative of the mineralization hosted on the project.Qualified PersonsThe technical content of this news release has been reviewed and approved by Michael Dufresne, M.Sc., P.Geol., P.Geo., an independent qualified person as defined by National Instrument 43-101.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288304 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Results Highlights:Revenue increased by 10.0% year-on-year to a record high of US$180.5 million, marking the fifth consecutive year of record-setting revenue performance.Sales volume hit a new high of 2.02 million units, representing a year-on-year increase of 16.2%.Gross profit rose by 7.0% to a record of US$122.4 million; profit attributable to owners of the Company rose by 5.5% to US$41.9 million.The Board has proposed a final cash dividend of HK12 cents per share, bringing the total cash dividend for the Year to HK27 cents per share alongside special dividend, representing a payout ratio of 68.4%.The Group remains in a robust financial position, with cash and bank balances of US$228.7 million at the end of the year for supporting potential acquisitions and the construction of new production facilities.Maintained revenue growth in major markets, with the Asia-Pacific market at 15.7%, the EMEA markets at 19.6%, and the US market at 37.0%.The Group actively leverages its sales network and expertise to assist high-quality medical device peers in selling their products globally, while diversifying its own product portfolio. One of the collaborative products has already been launched in Hong Kong, Malaysia, Germany, and Spain, and is progressively being rolled out to more markets in the APAC and EMEA regions.HONG KONG, Mar 12, 2026 - (ACN Newswire via SeaPRwire.com) – OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, today announced its annual results for the year ended December 31, 2025 (“FY2025” or the “Year”). Despite significant external challenges, the Group demonstrated remarkable resilience, achieving historic highs in revenue, sales volume, and gross profit, along with improved net profit.During the Year, OrbusNeich’s investments to strengthen its global sales and marketing capabilities, as well as expand product offerings, continued to yield positive results. The Group achieved revenue growth for the fifth consecutive year, reaching a record high of US$180.5 million. Additionally, sales volume in FY2025 hit a new high of 2.02 million units, representing a year-on-year growth of 16.2%, which included an increase of 13.1% from proprietary products and 34.9% from third-party products. Gross profit, up by 7.0% year-on-year, reached a record high of approximately US$122.4 million, with profit attributable to owners of the Company increasing by 5.5% to $41.9 million, and basic earnings per share rising by 5.8% to US5.09 cents.As at December 31, 2025, the Group maintained a strong financial position with cash and bank balances amounting to US$228.7 million. Taking into consideration OrbusNeich’s solid operating performance, healthy cash reserves and future capital requirements, the Board has proposed a final cash dividend of HK12 cents per share (2024: HK10 cents per share), up by 20% year-on-year. Alongside the special cash dividend of HK15 cents per share paid during the Year to celebrate OrbusNeich’s 25th anniversary and express gratitude for shareholders’ long-standing support, the total cash dividend for FY2025 will be HK27 cents per share.Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “Building on 25 years of expertise, OrbusNeich achieved another strong performance in FY2025. Our commitment to product innovation and quality, and the establishment of dedicated local teams in diverse markets ensures that our products benefit vascular disease patients worldwide. During the Year, the Group advanced its strategy of building a comprehensive sales network while forging strategic collaborations, including providing commercialization support for Chinese medical device companies expanding overseas. Meanwhile, construction of our R&D and manufacturing base in Hangzhou is progressing steadily, reflecting our long-term growth ambitions.”Extensive Global Sales Network Fuels Strong Multi-Regional Revenue and Business GrowthOrbusNeich maintains an extensive sales network covering over 70 countries and regions through its 12 direct sales teams and distributor network, which includes the acquisition of a Taiwan-based distributor during the Year. During FY2025, the APAC region experienced a significant year-on-year increase in revenue of 15.7%, climbing to US$60.5 million, driven by strong performance in existing direct sales markets and the addition of the Taiwan market. Revenue growth in the EMEA region accelerated, rising by 19.6% to US$46.9 million, supported by rapid growth of over 20% in direct sales markets such as Germany, France, and Spain, along with substantial growth in distributor markets. As the impact of tariffs eased and product demand remained strong, revenue from the US market grew by 37.0% year-on-year, reaching US$21.2 million. Meanwhile, revenue from the Japan and PRC markets totaled US$32.3 million and US$17.8 million, respectively.In the second half of the year, the Group focused on strengthening its market presence in Europe and established a direct sales team in the Netherlands. The Group is establishing another direct sales team in Belgium in 2026, with the goal of achieving direct sales to local hospitals in both markets within the same year.OrbusNeich’s robust global sales network has attracted various manufacturers to collaborate with the Group on international market expansion. During the Year, the Group strengthened its partnership with SonoScape Medical Corp. by distributing their IVUS products across key APAC and European markets, including direct sales regions like Singapore, Malaysia, France, Germany, Spain, and Switzerland, as well as selected distributor markets in Europe. The IVUS products began generating sales in Hong Kong, Malaysia, Germany, and Spain by the end of FY2025.Strengthening a Diversified Portfolio via Parallel Global Registrations and Clinical TrialsAs at December 31, 2025, OrbusNeich owned more than 220 granted patents and published patent applications in key jurisdictions worldwide, as well as 35 PMDA-approved products, 42 CE-marked products, 20 FDA-cleared or approved products, and 24 NMPA-approved products.During the Year, the Group achieved progress in product registrations and clinical trials, including:Obtained PMDA approvals for Teleport Glide, Scoreflex QUAD, EZGuide LL (Large Lumen), Vascuaid and SIDEPASS, CE Marks for JADE PLUS and Teleport Glide, and NMPA approvals for the GuidingArk guiding catheter and Teleport XT;Submitted applications for FDA approval of Teleport Glide, PMDA approvals of Sapphire ULTRA and Sapphire NC ULTRA, and NMPA approvals of Scoreflex TRIO, Teleport Glide, Sapphire NC 24, Sapphire NC ULTRA, Sapphire ULTRA and JADE PLUS;Completed patient enrollment for the US clinical trial of Sapphire 3, with product registration expected to be submitted to the FDA in the first half of 2026;Completed patient enrolment of clinical registries for eucatech AG’s product eucaLimus and SUPPORT C, while patient enrollment for VITUS is still ongoing, with the goal of renewing CE Marks for these products under MDR by the end of 2027;Developing the proprietary coronary paclitaxel drug-coated balloon, Sapphire PTX, with a clinical trial application expected to be submitted to the PMDA in Q1 2026;Developing the peripheral scoring balloon, JADE Score, with registration applications expected to be submitted to the PMDA and the FDA in 2026.Optimizing Global Production Layout for Sustained Long-Term GrowthThe Group’s facilities in Shenzhen, the PRC; Hoevelaken, the Netherlands; and Weil am Rhein, Germany, achieved a combined annual production capacity of approximately 2.1 million units of balloons and stents as at December 31, 2025. To meet future production needs, construction of OrbusNeich’s largest R&D and manufacturing facility in Hangzhou, the PRC, is underway. Following the topping-out ceremony in the second half of 2025, marking the completion of construction of the main structure, renovation work has been ongoing since the end of 2025. The new facility is expected to commence operation in 2027, adding an annual production capacity of 2.4 million units.Mr. Chien concluded, “Looking ahead to 2026, OrbusNeich will continue leveraging its global platform to navigate ongoing external challenges. With the launch of new proprietary and eucatech AG products, rising third-party product sales, and the shift from distribution model to direct sales in certain markets, we expect steady revenue growth in the future. The Group will also explore potential downstream acquisitions in Europe to further consolidate our brand position. Going forward, we aim to sharpen our commercialization edge, maintain leadership in innovation and quality, and explore new business models to drive growth. Ultimately, these initiatives will reinforce our global competitiveness and further our founder, Mr. Teddy Chien’s vision of ‘benefitting humanity’ by improving patients’ quality of life worldwide.”About OrbusNeich Medical Group Holdings LimitedOrbusNeich is a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, our Group sells its products in more than 70 countries and regions worldwide. It is also actively expanding into structural heart disease. With an in-house R&D team boasting over 20 years of product development expertise, our Group has developed world-leading proprietary technologies.For more information, please visit the Group’s official website: https://orbusneich.com/.Media InquiriesStrategic Financial Relations LimitedAngelus LauTel: (852) 2864 4805Email: angelus.lau@sprg.com.hkDoris HoTel: (852) 2114 4916Email: doris.ho@sprg.com.hkBailey ZhouTel: (852) 2114 2825Email: bailey.zhou@sprg.com.hkWebsite: https://www.sprg.com.hk/OrbusNeich Medical Group Holdings Limited                                                   Maggie LauTel: (852) 3109 7234Email: mlau@orbusneich.comLucille Tsang Tel: (852) 3109 7292Email: ltsang@orbusneich.comWebsite: https://orbusneich.com/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

業績亮點：收入同比增長10.0%至1.80億美元，連續五年創新高。銷量破紀錄，達202萬件，同比增長16.2%。毛利上升7.0％至1.22億美元新高；公司擁有人應佔利潤增長5.5%至約4,190萬美元。董事會建議派發末期股息每股12港仙，連同特別股息，本年度現金股息總額達每股27港仙，派息比率為68.4％。財務狀況穩健，年末現金及銀行結餘為約2.29億美元，支持潛在收購及新生產設施建設。主要市場收入繼續增長，亞太地區市場增長15.7％，歐洲、中東及非洲市場增長19.6%，及美國市場增長37.0%。集團積極透過其銷售網絡及專業知識，協助優質醫療器械同業的產品邁向全球，同時豐富自身的產品組合。其中一款合作產品已於香港、馬來西亞、德國及西班牙上市，並正逐步推廣至亞太及歐洲、中東及非洲地區更多市場。香港, 2026年3月12日 - (亞太商訊 via SeaPRwire.com) - 專營經皮冠狀動脈介入治療（PCI）及經皮腔內血管成形術（PTA）手術介入器械的全球醫療器械製造公司業聚醫療集團控股有限公司（「業聚醫療」或「集團」；股份代號：6929）今天宣佈截至2025年12月31日止年度（「2025財政年度」或「回顧年」）的全年業績。儘管外圍環境充滿挑戰，集團仍展現非凡韌性，收入、銷量及毛利齊創歷史新高，純利亦錄得增長。回顧年內，業聚醫療在強化全球銷售與營銷能力及擴大產品組合投資方面，繼續取得顯著成效。集團收入連續五年實現增長，達180.5百萬美元新高。2025財政年度銷量亦創新高，同比增長16.2%至202萬件，其中自有產品及第三方產品銷量分別增長13.1%及34.9%。毛利同比增長7.0％至122.4百萬美元，同創歷史高位；公司擁有人應佔利潤增長5.5%至41.9百萬美元。每股基本盈利上升5.8%至5.09美仙。於2025年12月31日，集團的財務狀況維持穩健，現金及銀行結餘達約228.7百萬美元。鑑於業聚醫療穩健的營運表現、充裕的現金儲備及考慮到未來資本需求，董事會建議派發末期現金股息每股12港仙（2024年：每股10港仙）。連同較早前為慶祝業聚醫療成立25周年及答謝股東長期支持而派發的每股15港仙特別現金股息，2025財政年度的現金股息總額為每股27港仙。業聚醫療董事長、執行董事兼首席執行官錢永勛先生表示：「業聚醫療憑藉過去25載建立的實力，於2025財政年度再創佳績。我們一直堅持產品創新與品質至上的承諾，並建立專業團隊紮根全球各主要市場，確保產品可惠及世界各地的血管疾病患者。本年度，集團持續擴展全球銷售網絡，同時推進多項策略性合作，包括為期望進軍海外市場的中國醫療器械企業提供商業化支持。同時，我們位於杭州的研發及生產基地建設進展順利，充分展現集團尋求長遠增長的決心。」銷售網絡遍及全球，推動多區域收入及業務強勁增長業聚醫療的龐大銷售網絡，是由12個直銷團隊（包括本年度收購的一家台灣分銷商）及分銷商網絡組成，遍及全球70多個國家和地區。2025財政年度，有賴現有直銷市場的強勁表現及台灣市場的額外貢獻，亞太地區收入同比大幅增長15.7%至60.5百萬美元；歐洲、中東及非洲地區方面，德國、法國及西班牙等直銷市場錄得逾20.0%的快速增長，分銷商市場亦增長顯著，帶動該區整體收入加速增長，上升19.6%至46.9百萬美元。而隨關稅影響緩解加上產品需求持續強勁，美國市場收入同比增長37.0%至21.2百萬美元。而日本及中國內地市場的收入分別為32.3及17.8百萬美元。下半年，集團重點強化歐洲市場佈局，在荷蘭建立了直銷團隊。2026年，集團正於比利時設立另一直銷團隊，以期在同年於兩地市場實現向醫院直銷。業聚醫療廣泛的全球銷售網絡吸引了眾多製造商攜手合作，共同拓展國際市場。本年度，集團深化與深圳開立生物醫療科技股份有限公司的合作，於多個亞太及歐洲主要市場分銷其血管內超聲（IVUS）產品，涵蓋新加坡、馬來西亞、法國、德國、西班牙、瑞士等直銷市場，以及歐洲數個選定的分銷市場。於2025財政年底前，該產品已於香港、馬來西亞、德國及西班牙市場實現銷售。全球註冊與臨床齊頭並進，強化多元創新產品組合截至2025年12月31日，業聚醫療在全球主要司法管轄區擁有超過220項授權專利及已公佈專利申請，包括35款獲PMDA批准產品、42款獲CE標誌產品、20款獲FDA許可產品及24款獲國家藥監局批准產品。本年度，集團在產品註冊及臨床試驗方面繼續取得進展，包括：Teleport Glide、Scoreflex QUAD、EZGuide LL（大管腔）、Vascuaid及SIDEPASS獲PMDA批准，JADE PLUS及Teleport Glide獲CE標誌，GuidingArk導引導管及Teleport XT獲國家藥監局批准；就Teleport Glide向FDA提交檢准申請、就Sapphire ULTRA及Sapphire NC ULTRA向PMDA提交批准申請；就Scoreflex TRIO、Teleport Glide、Sapphire NC 24、Sapphire NC ULTRA、Sapphire ULTRA及JADE PLUS向國家藥監局提交批准申請；完成Sapphire 3美國臨床試驗的病人入組工作，預計於2026年上半年向FDA提交產品註冊申請；完成eucatech AG旗下產品eucaLimus及SUPPORT C的臨床登記的病人入組，並進行VITUS的病人入組工作，目標於2027年底前取得MDR下的CE標誌認證；開發自有冠狀動脈紫杉醇藥物塗層球囊Sapphire PTX，預計於2026年第一季向PMDA提交臨床試驗申請；開發外周刻痕球囊JADE Score，預計於2026年向PMDA及FDA提交註冊申請。優化全球產能佈局，實現可持續的長遠增長集團位於中國深圳、荷蘭荷佛拉肯及德國萊茵河畔魏爾的生產設施，於2025年12月31日的球囊及支架年產能達約210萬件。為滿足未來生產需要，集團正於中國杭州興建旗下最大型的研發及生產設施。項目封頂儀式已於2025年下半年舉行，標誌該設施主體結構工程竣工，裝修工程亦於2025年底啟動。新設施預計於2027年投入營運，屆時將新增年產能240萬件。錢先生總結：「展望2026年，業聚醫療將繼續善用全球平台應對當前外圍挑戰。隨著自有新產品及eucatech AG產品推出、第三方產品銷量持續增長，以及部分市場由分銷轉向直銷模式，我們預期未來收入將穩步上升。集團亦將於歐洲物色潛在的下游收購目標，以進一步鞏固品牌地位。未來，我們將繼續強化商業化方面的競爭優勢，保持產品創新與卓越品質方面的領先地位，並積極探索新業務發展模式，以達致增長。這些舉措不僅能鞏固集團的全球競爭力，更將延續創始人錢學雄先生『造福人群』的初心與使命，為全球患者帶來更美好的生活。」關於業聚醫療集團控股有限公司業聚醫療是一家全球醫療器械製造公司，專門生產用於經皮冠狀動脈介入治療（PCI）及經皮腔內血管成形術（PTA）的介入器械。本集團總部位於中國香港，產品銷往全球超過70個國家和地區。集團亦積極將業務擴展至結構性心臟病領域。憑借擁有逾20年產品開發經驗的內部研發團隊，本集團已開發出世界領先的專有技術。如需瞭解詳情，請訪問集團官網：https://orbusneich.com/傳媒垂詢縱橫財經公關顧問有限公司劉若琪電話：(852) 2864 4805電郵：angelus.lau@sprg.com.hk 何田田電話：(852) 2114 4916電郵：doris.ho@sprg.com.hk周百霖電話：(852) 2114 2825電郵：bailey.zhou@sprg.com.hk 網站: www.sprg.com.hk業聚醫療集團控股有限公司劉慧菁電話：(852) 3109 7234電郵：mlau@orbusneich.com曾　璐電話：(852) 3109 7292電郵：ltsang@orbusneich.com網站: https://orbusneich.com/ Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 12, 2026 - (ACN Newswire via SeaPRwire.com) – As the average age of the global population continues to rise, the Chinese Mainland is now home to the world’s largest number of seniors. Recognising this, the country’s 15th Five-Year Plan calls for proactive measures to address the challenges of an increasingly ageing population. The silver economy is set to be one of the vital engines for the mainland's next wave of economic growth.The Hong Kong Trade Development Council (HKTDC) has released a new consumer survey report, Chinese Mainland Silver Economy Opportunities, that details the strong spending power of the mainland’s affluent, middle-class senior consumers, as well as the vast untapped potential of this particular sector of society. With securing "happiness" and ensuring "quality" as their spending priorities, the survey shows that such consumers regard Hong Kong-made products as guaranteed to be authentic, while the city’s services sector is seen as professional and reliable. As a result, many of these consumers pronounce a willingness to pay a "Hong Kong premium".Believing that the continued expansion of the mainland's silver economy represents significant opportunities for Hong Kong businesses, Bruce Pang, HKTDC Director of Research, said: "Among other priorities, the 15th Five-Year Plan focuses on boosting domestic demand as a means of driving economic growth. Inevitably, this will create opportunities for Hong Kong companies looking to expand into the Chinese Mainland market.“By gaining a deeper understanding of the consumption patterns of mainland seniors, particularly those in the higher-spending middle-class and affluent segments, Hong Kong businesses will be able to effectively penetrate the domestic market."To gain a more in-depth understanding of the development opportunities in the country’s silver economy, HKTDC surveyed more than 2,000 middle-class/affluent senior consumers in various mainland cities last year. The broad cross-section of respondents included those in their 50s starting to plan their retirement, those entering retirement in their 60s, and the older post-retirement population (aged 70 and above). According to the survey’s findings, respondents' average monthly expenditure on daily consumer goods and services was approximately RMB7,000, rising to RMB8,000 for those in first-tier cities.Commenting on the findings of the survey, Wing Chu, the HKTDC’s Deputy Director of Research, who led the study, said: "Currently, the Chinese Mainland's silver economy is valued at about RMB7 trillion – some 6% of overall GDP. This is projected to surge to RMB30 trillion by 2035, indicating the segment’s huge development potential.“The survey also showed that more than half of such consumers had purchased Hong Kong products or services, consequently holding Hong Kong brands in particularly high regard. It was also notable that 78% of respondents were willing to pay a premium for Hong Kong-sourced products, while 84% were willing to do so in the case of the city’s services sector. Typically, respondents were willing to pay a 16.4% premium on products and 15.4% premium on services, with those in first-tier cities happy to pay an even higher percentage for many types of products and services.”Hong Kong brands enjoy stellar reputationOverall, many of the mainland’s senior consumers have a highly positive view of Hong Kong brands, with the city’s products celebrated for their quality and authenticity, and its services for their professionalism and reliability. On the product front, 61% of respondents had purchased Hong Kong products in the past year, including health foods (24%), luxury goods (18%) and beauty and personal care products (17%). In terms of future purchases, respondents expressed the greatest interest in Hong Kong health foods, leisure foods and beverages.Regarding the city’s services, 54% of senior respondents said they had utilised Hong Kong services in the past year, including beauty and personal care services (25%), travel to Hong Kong, Macao and Taiwan (22%) and financial and wealth management services (20%). Over the next 12 months, the most sought-after Hong Kong services were said to relate to health and wellness services, followed by beauty and personal care services.Digging deeper into the preferences of such consumers, HKTDC Economist Eric Chu said: "When choosing products and services, happiness is the priority for Chinese Mainland seniors, closely followed by value for money. With this in mind, Hong Kong businesses can leverage the silver economy by capitalising on the strong reputation and professional advantages of the city’s brands.“Specifically, they should consider expanding into the higher-spending first and second-tier cities, while targeting the younger segment of the senior population. Enhancing the offline experience and fostering word-of-mouth recommendations, alongside optimised promotional efforts, will also help Hong Kong businesses stand out in the mainland’s rapidly growing silver market.”Silver generation shaping a “blue ocean” of consumptionTaking a more in-depth look at the survey findings, 65% of respondents prioritised products or services that would enhance their leisure or bring them happiness, while 63% valued reasonable pricing and good value for money, and 62% focused more on the practicality and durability of the products or services on offer. Collectively, this indicates that mainland seniors are particularly concerned about their health and quality of life, while also valuing cost-effectiveness and functionality, marking them out as a notably mature and rational consumer group.In terms of product consumption, 23.3% of respondents most frequently purchased food and beverages, followed by home products (12.6%) and clothing (12.5%). In the case of services, 20.3% utilised body wellness services most often, followed by beauty and personal care services (16.7%) and leisure and entertainment services (13.1%).In addition, despite the popularity of online shopping across the mainland, the survey showed that physical stores remain the primary consumption channel for the more elderly demographic. For such consumers, offline experiences, in-person consultations and a sense of trust in products and services remain prime considerations.To help businesses capitalise on opportunities arising from the silver economy market, the HKTDC has incorporated various related elements into many of its exhibitions and forums. This allows relevant companies to showcase their products and technologies, while also giving them the opportunity to explore the latest industry developments through a series of related seminar programmes.Aligning with this approach, a thematic seminar on healthy ageing was held as part of the Asia Summit on Global Health, while the Rehabilitation and Elderly Care zone at the Hong Kong International Medical and Healthcare Fair featured the latest gerontechnology products. The Hong Kong Electronics Fair (Autumn Edition) also sought to showcase fitness and health products relevant to the senior market.In addition, the Hong Kong Toys & Games Fair, held in January this year, introduced a new “Happy Ageing” label for silver market products, making it easier for buyers to identify toys and related products designed specifically for older consumers. The Asia Toys & Games Forum, held during the fair, hosted a discussion by a number of international experts on the optimum design of toys for the elderly, while also offering many other insights into the silver-focused toy market.Looking ahead, the HKTDC will continue to provide comprehensive support to the business sector, enabling enterprises to further explore and develop opportunities in the growing silver economy market.ReferencesReport link: https://research.hktdc.com/en/article/MjI2ODIyMDg0NwHKTDC Research: http://research.hktdc.com/enPhoto download: https://bit.ly/4shpQjOHKTDC Director of Research Bruce Pang (centre), Deputy Director of Research Wing Chu (left) and Economist Eric Chu (right) presented key findings from the "Chinese Mainland Silver Economy Opportunities" consumer survey reportHKTDC Media Room: http://mediaroom.hktdc.com/enMedia enquiriesFor enquiries, please contact:Raconteur PR Agency:Betsy TseTel: (852) 9742 7338Email: betsytse@raconteur.hkMolisa LauTel: (852) 6187 7786Email: molisalau@raconteur.hkHKTDC Communication and Public Affairs Department:Clayton LauwTel: (852) 2584 4472Email: clayton.y.lauw@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 12, 2026 - (ACN Newswire via SeaPRwire.com) – Mint Incorporation Limited (“Mint” or the “Group”, NASDAQ: MIMI), a Hong Kong-based company with a new strategic focus on artificial intelligence (AI) and robotics, and an established business interior design and fit-out works provider, today announced that its wholly-owned subsidiary, Axonex Intelligence Limited (“AXONEX”)  has entered into a joint venture agreement (the “JV Agreement”) with Synergy Technology Group Limited (“STG”) to establish Axonex Automation Limited (“JV company”), a new Hong Kong-based joint venture company focused on commercializing advanced digital twin and drone flight control technologies in Hong Kong and selected overseas markets.Under the JV Agreement, AXONEX will hold an 80% equity interest in Axonex Automation Limited, while STG will hold the remaining 20%. The joint venture will combine AXONEX’s operational resources and international business capabilities with STG’s proven technology in digital twins and drone flight control systems to drive scalable deployment in sectors such as infrastructure inspection, utilities, smart cities, and industrial operations.AXONEX has committed to provide up to HK$ 20,000,000 of capital to the joint venture in stages, subject to the achievement of defined business and technical milestones set out in the agreement. The funding will be released through four tranches over an expected 12–24-month period.STG will contribute technology, intellectual property, know-how, and ongoing technical support to the JV company, initially via a license of its core digital twin and drone flight control platforms, the “Zhishan No-Code Digital Twin Universal Platform and related drone inspection technologies” to Axonex Automation Limited.Mr. Damian Chan, Chairman of the Board and Chief Executive Officer of Mint stated: “This joint venture creates a focused vehicle to bring next-generation digital twin and autonomous drone capabilities from concept to commercial reality across Hong Kong and key overseas markets.”A representative of Synergy Technology Group Limited added: “Our collaboration with AXONEX will accelerate the real-world adoption of our digital twin and drone flight control technologies in critical infrastructure, smart city, and industrial applications, leveraging Hong Kong as a launchpad for global expansion.”Photo CaptionMr. Damian Chan, Chairman of the Board and Chief Executive Officer of Mint (Right) and Mr. Jiang Xiaotong, founder of STG (Left) signed the JV to establish Axonex Automation Limited focused on commercializing advanced digital twin and drone flight control technologies in Hong Kong and selected overseas markets.About Mint Incorporation LimitedMint Incorporation Limited (NASDAQ: MIMI), a Hong-Kong based enterprise listed on NASDAQ, specializes in artificial intelligence (AI), robotics, and interior design. Through its subsidiary Axonex Intelligence Limited, the company delivers intelligent robotics and facility management solutions to enterprises, real estate, shopping centers, government agencies, and more. Mint also operates Matter International Limited, providing professional interior design and renovation services. With a focus on innovation and practical applications, Mint is committed to enhancing efficiency, safety, and quality of life across industries.About Synergy Technology Group LimitedSynergy Technology Group Limited is a Hong Kong-based technology company specializing in advanced digital twin solutions and drone flight control systems, with applications across infrastructure monitoring, utilities, and smart city ecosystems. Founded by Jiang Xiaotong, an Associate Professor at Southeast University, Synergy Technology Group Limited operates under a license from Nanjing Zhishan Intelligent Technology Research Institute Co., Ltd for the “Zhishan No-Code Digital Twin Universal Platform and related drone inspection technologies”.Forward-Looking StatementsCertain statements in this release are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results disclosed in the Company’s filings with the SEC. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月12日 - (亞太商訊 via SeaPRwire.com) - Mint Incorporation Limited（「Mint」或「集團」，納斯達克股票代碼：MIMI）─ 一家專注於人工智能與機械人技術，同時提供商業室內設計及裝修服務的香港本地企業，今日欣然宣布，其全資子公司 Axonex Intelligence Limited （「AXONEX」）已與互惠智科有限公司（「互惠智科」）訂立合資協議，共同成立Axonex Automation Limited（「合資企業」），一家總部位於香港，專注香港及特定海外市場將先進的數字孿生及無人機飛行控制技術商業化的新合資企業。根據合資協議，AXONEX將持有Axonex Automation Limited 80%的股權，而互惠智科將持有其餘20%。這合資協議將結合AXONEX的營運資源與國際業務能力，及互惠智科在數字孿生與無人機飛行控制系統領域的成熟技術，以推動在基礎設施檢測、公用事業、智慧城市及工業營運等領域的可規模化部署。AXONEX 已承諾按階段向合資企業投入最高達20,000,000港元的資金，具體金額將按協議所訂明的業務及技術里程碑的達成情況而擬定。相關資金預計將於12至24個月期間內分四期撥付。互惠智科將向合資企業提供技術、知識產權、專業技能及持續的技術支援，初期將向Axonex Automation Limited授權其「止善零代碼數字孿生通用平台」及無人機巡檢相關業務。Mint董事會主席兼行政總裁陳海龍先生表示：「是次與互惠智科的合資協議將創建一個平台，專注將新一代數字孿生及自動駕駛無人機技術，在香港及多個重要海外市場從概念階段推向商業應用。」互惠智科有限公司的代表補充道：「與AXONEX的合作將加速我們的數字孿生及無人機飛行控制技術在關鍵基礎設施、智慧城市及工業應用領域的實際落地，並以香港為起點，實現全球業務拓展。」圖片說明Mint董事會主席兼行政總裁陳海龍先生（右）與互惠智科創辦人姜曉彤先生（左）簽署合資協議，共同成立Axonex Automation Limited，專注香港及特定海外市場將先進的數字孿生及無人機飛行控制技術商業化。有關Mint Incorporation LimitedMint Incorporation Limited（納斯達克股票代碼：MIMI）是一家於納斯達克上市的香港本地企業，專注於人工智能、機械人技術及室內設計領域。透過其子公司 Axonex Intelligence Limited，公司為企業、地產、商場、政府機構等提供智能機械人與設施管理解決方案。Mint 同時營運 Matter International Limited，提供專業室內設計與裝修服務。秉持創新與實際應用並重的理念，Mint 致力於提升各行各業的效率、安全性與生活質素。有關互惠智科有限公司互惠智科有限公司是一家總部位於香港的科技企業，專門提供先進的數字孿生解決方案及無人機飛行控制系統，其應用領域涵蓋基礎設施監測、公共設施及智慧城市生態系統。由東南大學副教授姜曉彤創立，互惠智科有限公司獲南京止善智能科技研究院有限公司所授予的許可，營運「止善零代碼數字孿生通用平台」及「無人機巡檢」相關業務。前瞻性陳述本新聞稿中的某些陳述屬於前瞻性陳述。這些前瞻性陳述涉及已知和未知的風險和不確定性，並基於公司對可能影響其財務狀況、營運成果、業務策略和財務需求的未來事件的目前期望和預測。投資者可通過「大約」、 「相信 」、 「希望 」、 「期望 」、 「預期 」、 「估計 」、「項目 」、 「打算 」、 「計劃 」、 「將 」、 「將會 」、 「應該 」、 「可能 」或其他類似的詞語或短語識別這些前瞻性陳述。公司不承擔更新或修訂任何前瞻性陳述以反映隨後發生的事件或情況，或其期望的變化的公開義務，除非法律要求。儘管公司認為這些前瞻性陳述所表達的期望是合理的，但無法保證這些期望將會被證實正確，並提醒投資者實際結果可能與預期結果有顯著差異，並鼓勵投資者查閱可能影響其未來結果的其他因素，這些因素披露在公司向證券交易委員會提交的文件中。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Shantou China, Mar 12, 2026 - (ACN Newswire via SeaPRwire.com) - From March 18 to 20, 2026, the 5th China Chaoshan International Textile and Garment Exhibition will be held at the Shantou International Convention & Exhibition Center, under the theme “Five Continents Gather in Chaoshan”.This year, the Exhibition has been fully upgraded in scale, covering over 150,000 square meters and featuring more than 100 product categories. It will bring together over 1,200 exhibitors showcasing more than 200,000 new products and bestsellers, and is expected to attract over 140,000 professional buyers seeking business opportunities.The buyers come from hundreds of cities and provinces across China, as well as more than 40 countries and regions overseas, encompassing Chinese and international purchasers, both online and offline buyers. The audience spans all channels, including e-commerce shelves, livestream e-commerce, cross-border platforms, ready-to-wear brands, private domain/group purchases, overseas trade, agents/distributors, brick-and-mortar chains, supermarkets/department stores, and well-known IPsThe appeal of the Exhibition lies in the quality and quantity of professional attendees. The 5th China Chaoshan International Textile and Garment Exhibition precisely matches the product categories of exhibitors with the needs of buyers, efficiently connecting partners and attracting the top procurement representatives across key channels within the industry, offering exhibitors unprecedented business opportunities.It brings together leading internet fashion brands and buyers, such as Bananain, Beneunder, NEIWAI, and Luckymeey, who drive online market growth and provide exhibitors with a golden channel for scalable exposure and precise user reach.Top KOLs, leading MCN (Multi-Channel Network) agencies, and livestreamers will unlock traffic potential, becoming a new engine for brands to amplify both awareness and sales.Leading lingerie retail chains integrate resources to efficiently meet the end-market procurement needs, building a stable, high-end channel network and providing brands with solid market penetration capabilities.Core regional agents and channel leaders in provincial and city-level markets cultivate local distribution networks and end-market operations, helping products achieve deeper market penetration and channel expansion.The Exhibition also gathers national-level chain supermarkets, high-end department store groups, and large shopping centers, providing large-scale physical venues that lay a solid foundation for offline retail partnerships.Mainstream cross-border platforms such as Amazon, eBay, SHEIN, and TEMU, along with major international and local e-commerce sellers, will participate, opening full-chain overseas opportunities for brands and helping enterprises enter the global textile and apparel consumer market.Representatives from leading e-commerce platforms, including Alibaba, POIZON, JD.com, Douyin, and VIP.com, will attend to connect with exhibitors, sharing insights on platform traffic and algorithm trends to drive online bestsellers and omni-channel growth.Top buyers from well-known lingerie brands will serve as partners guiding professional trends. Representatives from leading lingerie brands such as Aimer, Gujin, HODO, and FENTENG will be present, providing buyers with a fast-track to the full range of lingerie products.Top buyers from apparel brands bring mature brand matrices and customer bases, providing strategic channels to expand product reach and serve as partners in market breakthroughs and value enhancement.Invitations for professional buyers to the 5th China Chaoshan International Textile and Garment Exhibition are still ongoing, helping you explore more opportunities in the industry, secure real orders, and establish meaningful partnerships. We warmly invite industry friends to join us on-site and participate in this grand event!March 18 to March 20, 2026Shantou International Convention & Exhibition CenterWe sincerely invite you to attend and explore new opportunities in the industry.Media contactCompany Name: Shantou Zhongbo Exhibition Co., Ltd.Contact Person Name: James XiaoContact Person Title: General Manager AssistantOfficial Website: www.ctge.net/en/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 11, 2026 - (ACN Newswire via SeaPRwire.com) – Yuexiu Real Estate Investment Trust ("Yuexiu REIT", together with Yuexiu REIT Asset Management Limited, collectively known as the “REIT”; stock code: 405) announced its annual results for the year ended 31 December 2025.Yuexiu REIT Management Team: Chairman and Non-Executive Director Mr. JIANG Guoxiong (center), Executive Director and Chief Executive Officer Ms. OU Haijing (left), and Chief Financial Officer Mr. KWAN Chi Fai (right)2025 Annual Results Highlights:                                                    - Overall operation remained resilient, with total revenue of RMB1,856 million (2024: RMB2,032 million).- The average financing cost was 3.61%, a three-year low; the average interest payment rate was 3.77%, representing a year-on-year decrease of 76 basis points. Excluding exchange loss, the financing expenses decreased by approximately RMB152 million year-on-year.- As at 31 December 2025, the overall occupancy rate of the properties was 82.1% (2024: 84.5%).- Optimised the asset portfolio by disposing of a 50% interest in Yuexiu Financial Tower in Q4 2025, realising cash proceeds of approximately RMB5.3 billion to enhance financial flexibility. Yuexiu REIT maintained its "investment-grade" rating from both Standard & Poor's and Fitch, with the outlook upgraded to "stable".- The final distribution to the Unitholders for the period will be approximately RMB0.0189, equivalent to HK$0.0214. Distribution per Unit for the year will be approximately RMB0.0522, equivalent to HK$0.0580. Distribution yield is 6.74% per Unit for the year.- To maintain the REIT’s financial flexibility, the distribution ratio for the period from 1 July 2025 to 31 December 2025 has been adjusted to 90%, resulting in an overall full-year distribution ratio of approximately 96%.Guangzhou International Finance Center (GZIFC):- Operating revenue of the GZIFC complex was RMB984 million, accounting for 53.0% of the REIT’s total revenue.- The office building of GZIFC introduced two Fortune Global 500 companies; the occupancy rate was 80.9%.- GZIFC Shopping Mall introduced China Duty Free Group (CDFG), the first and currently the only downtown duty-free store in Guangzhou, achieving a renewal rate of 89% for the year, and an occupancy rate of 95.5% at the end of the period.- Four Seasons Hotel Guangzhou's average room rate increased by 5.8% year-on-year. Ascott Serviced Apartments GZIFC achieved an average occupancy rate of 91.5%, up 1 percentage point year-on-year, with revenue reaching a record high for the period.Proactive Management of Financing Risk and Effective Stabilisation of Financing Cost- With regard to the short-term loan of RMB530 million, the 5-year syndicated loan of HK$2.1 billion, and the remaining HK$2.1 billion of the 3-year syndicated loan of HK$3.8 billion, all due in 2025, the Manager in 2025 renewed the short-term loan of RMB530 million, obtained offshore loan of RMB1.7 billion, issued dim sum bonds of RMB1 billion, and obtained an offshore syndicated loan package equivalent to HK$2.1 billion (a sustainability-linked loan), for the refinancing of the maturing loans so as to ensure effective monitor on the liquidity risk.- A total of approximately RMB4.68 billion in loans were obtained in 2025 to partially refinance offshore HKD floating rate loans, taking advantage of the relatively low-cost of RMB financing to proactively adjust the financing structure. At the end of 2025, the financing interest rate exposure of Yuexiu REIT was approximately 10%, narrowed by 16 percentage points from 26% at the beginning of the year; the average financing cost was 3.61%, a three-year low, representing a decrease of 55 basis points from 4.16% at the beginning of the year; the average interest payment rate for the full year of 2025 was 3.77%, representing a year-on-year decrease of 76 basis points. Excluding the exchange loss, the finance expenses were approximately RMB773 million, representing a year-on-year decrease of approximately RMB152 million.- As at the end of 2025, Yuexiu REIT had RMB financing of approximately RMB15.47 billion, accounting for 76% of total financing (2024: RMB financing of approximately RMB12.33 billion, accounting for 60% of total financing).Mr. JIANG Guoxiong, Chairman and Non-Executive Director of Yuexiu REIT, said, "2025 marked the 20th anniversary of Yuexiu REIT's listing. The Manager consolidated its competitive advantages by taking strategic actions to secure market share, prioritised occupancy rates, strengthened risk control to stabilise lease renewals, enhanced product competitiveness to meet market demand and invested in capital renovation projects to ensure asset value preservation and appreciation. These efforts stabilised the fundamentals of operations in a challenging market, providing solid support for the full-year revenue. Concurrently, we optimised the asset portfolio by appropriately reducing the proportion of office buildings, and proactively captured favourable financing opportunities, successfully issuing the first-ever Panda Bonds by a listed REIT globally as well as the REIT’s inaugural green bond. Financing costs for the year reached a three-year low, effectively underpinning the overall distribution level. The successful execution of a series of pioneering capital operations fully demonstrated the Manager’s strategic commitment to driving the high-quality development of Yuexiu REIT. This underscored its resolute determination in creating sustainable and long-term value for Unitholders.”Guangzhou International Finance Center (GZIFC)During the year, GZIFC recorded a newly contracted area of 15,702 sq.m. The newly launched 7,403 sq.m. of furnished units recorded an absorption cycle of about 36 days, with an absorption rate close to 72%. Quality tenants introduced include two Fortune Global 500 companies, a Fortune China 500 company, a leading global shipping giant, and a renowned Internet-based culture, sports and entertainment company. In addition, the project recorded a renewal area of 34,294 sq.m. and a renewal rate of 86%, retaining quality tenants including six Fortune Global 500 companies and a foreign consulate. GZIFC was selected as one of the Top 30 companies in the “Performance Index - 2025 Commercial Property Operation Performance)” by Guandian.GZIFC Shopping Mall renewed lease with its anchor tenant, Guangzhou Friendship Store, and introduced China Duty Free Group (CDFG) to set up a store, which is the first and currently the only downtown duty-free store in Guangzhou. In addition, GZIFC Shopping Mall launched the light meal and beverage area on the basement floor, coupled with the brand revitalisation of the dining tenants on the fourth and fifth floors by introducing seven “first stores”. Membership operations achieved remarkable results, with the share of member sales doubling to 16%. The project actively created digitalised consumption scenarios and made full use of mainstream platforms to attract customer flow through multiple channels. Specifically, the “Italian Culture Season” themed event was successfully held in collaboration with hotels, theaters, museums and consulates, effectively boosting customer flow and sales. Newly contracted area and renewal area totaled 35,573 sq.m., with a renewal rate of 89%. The occupancy rate was 95.5%.Four Seasons Hotel Guangzhou launched the first batch of renovated rooms during the year. The average room rate was RMB2,260, representing a year-on-year increase of 5.8%. The average occupancy rate was 77.7%. The revenue per available room (RevPAR) was RMB1,756, representing a year-on-year increase of 0.9%. The RevPAR competitive index was 110.0, maintaining a relatively leading market position among luxury hotel competitors. Ascott Serviced Apartments GZIFC recorded an average occupancy rate of 91.5% during the year, representing a year-on-year increase of 1 percentage point. The average room rate was RMB1,137, representing a year-on-year increase of 1.6%. The RevPAR was RMB1,040, representing a year-on-year growth of 2.7%. The RevPAR competitive index reached 146.9, remaining at a high level among high-end apartment competitors. The Apartments achieved a record high in operating revenue for the same period and ranked first in operating revenue among Ascott China properties for ten consecutive years since 2016.Yuexiu Financial TowerThe Manager disposed of 50% interest in Yuexiu Financial Tower in Q4 2025. Following completion of the disposal, Yuexiu Financial Tower became a Qualified Minority-owned Property of the REIT. The occupancy rate was 77.9% at the end of the period.White Horse BuildingWhite Horse Building introduced high-quality customers from core industrial clusters in Guangzhou, Shenzhen and Dongguan and recorded a newly contracted area of 5,808 sq.m. for the year, with full occupancy on the 1st floor for the first time in the past five years and a six-year record high set by the 2nd floor’s occupancy rate. During the year, it organised 22 original brands to showcase their products at professional exhibitions such as the Fashion World Tokyo, and the China International Fashion Fair; held the “White Horse Fashion Journey: Border Trade Supply Chain Matching Conference”, and established the “Guangdong-Xinjiang Fashion Industry Chain Supply and Procurement Cooperation Alliance” with ten wholesale markets in Urumqi, Xinjiang. During the year, it welcomed a total of 517 procurement delegations, along with nearly 13,000 purchaser visits, including 19 foreign delegations from France, Vietnam and other countries, and facilitated procurement deals worth RMB320 million. The occupancy rate was 96.0% at the end of the period.Fortune PlazaDuring the year, the project recorded a newly contracted area of 6,334 sq.m., and introduced certain quality tenants including several subsidiaries of a Fortune Global 500 integrated financial group, two Fortune Global 500 companies and the Guangzhou branch of two global leading companies. The project recorded a renewal area of 8,662 sq.m. and a renewal rate of 84.0%, retained quality tenants including three Fortune Global 500 companies and the Guangzhou branch of a national commercial bank. Upgraded product standards accelerated the absorption of vacant units, with an absorption rate of 93% for furnished units. The occupancy rate was 93.4% at the end of the period, representing a year-on-year increase of 1 percentage point, and a strong rebound of 5.4 percentage points from the interim period.City Development PlazaDuring the Reporting Year, the project recorded a newly contracted area of 9,279 sq.m. and introduced a beauty technology company and a pharmaceutical supply chain service company to enhance the ambience of healthcare business in the building. The project recorded a renewal area of 5,011 sq.m. and a renewal rate of 77%, retained tenants including a Fortune Global 500 company and a globally-renowned Contract Research Organisation (CRO). The occupancy rate was 90.6% at the end of the period.Victory PlazaVictory Plazq’s anchor tenant, Uniqlo, continued to play a flagship role, recording a 7.0% year-on-year sales growth for the year and maintaining its position as the top-selling store nationwide. The project successfully introduced the sports brand “Super Anta” to set up the largest store in the Guangzhou-Foshan region and “Crab Mang Mang”, the first store nationwide of Guizhou spicy crab business, achieved the diversification of its food and beverage brand portfolio. By connecting internal and external resources to hold fifteen major events, the mall achieved a year-on-year increase of 2.0% in its annual sales. During the year, newly contracted area and renewal area totaled 5,579 sq.m., with a renewal rate of 84%. The occupancy rate was 94.0% at the end of the period.Shanghai Yue Xiu TowerDuring the year, Shanghai Yue Xiu Tower recorded a renewal area of 6,430 sq.m., with a renewal rate of 43%, while securing a newly contracted area of 8,070 sq.m., efficiently making up for the prematurely vacated units. During the year, the project continued to increase the supply of small-area furnished units to meet market demand, formulated differentiated pricing strategies, and successfully held a channel recruitment conference, which attracted more than one hundred real estate agencies. By investing in various capital nature renovations, the project enhanced both energy efficiency and service standards. The occupancy rate was 83.1% at the end of the period.Wuhan PropertiesDuring the year, Wuhan Yuexiu Fortune Centre recorded a newly contracted area of 26,837 sq.m., and introduced quality tenants including two Fortune Global 500 state-owned enterprises, and two Fortune Global 500 foreign enterprises. In addition, it recorded a renewal area of 20,617 sq.m. and a renewal rate of 76.0%, hitting a new high in the past three years, and retained quality tenants, including seven Fortune Global 500 enterprises and a Fortune China 500 company. Approximately 21,000 sq. m. of renovated units were supplied throughout the year, with an absorption rate approaching 98%. The occupancy rate was 62.1% at the end of the period, representing a year-on-year increase of 1 percentage point.Wuhan Starry Victoria Shopping Centre revitalised several popular dining and fitness brands, aiming to attract more family and young customer groups. The project deeply tapped into the consumption potentials of “night economy” and “scene experience” by leveraging the unique venue feature of “Joy Garden”, launching themed activities such as “Riverside Starry Night ”, thus achieving customer flow substantially in line with last year, while the shopping mall recorded a year-on-year increase of 0.5% in annual sales. During the year, newly contracted area and renewal area totaled 9,827 sq.m., with a renewal rate of 48.0%. The occupancy rate was 87.4% at the end of the period, representing a rebound of 5.0 percentage points from the interim period.Hangzhou VictoryDuring the year, the project recorded a newly contracted area of 7,890 sq.m. and introduced a tenant to take up an entire floor. In addition, it recorded a renewal area of 8,836 sq.m. and a renewal rate of 54%, retained quality tenants including two Fortune Global 500 companies and the Zhejiang branch of a state-owned enterprise in Shanxi Province. The occupancy rate was 84.5% at the end of the period.Integrating ESG into Business and Promoting Sustainable DevelopmentAdhering to a long-term perspective, the Manager systematically advanced ESG initiatives. On the occasion of publicly disclosing Yuexiu REIT’s sustainability practices for the tenth consecutive year, the Manager officially renamed the “Environmental, Social and Governance Report” to the “Sustainability Report”, further promoting the deep integration of Yuexiu REIT’s strategy into sustainable development and reinforcing their synchronized progress. During the year, Yuexiu REIT received the highest Green Five Star rating and the title of “Global Sector Leader” for the first time from the Global Real Estate Sustainability Benchmark (GRESB) and once again secured A-rating (highest level) for public disclosure, highlighting its outstanding capabilities in the field of sustainable development.ProspectsIn the coming year, the Manager will maintain a prudent and optimistic attitude, adapt proactively to changes and strengthen risk managemen to generate stable return for the Unitholders. In terms of asset management, the Manager will dynamically implement proactive, prudent and flexible leasing and operating strategies in response to economic development trends and competitive dynamics, diligently explore new growth drivers, and keenly seize potential opportunities to enhance the market competitiveness of asset portfolio. In terms of financing management, the Manager will continue to review and make reasonable adjustments to its financing structure, and introduce low-cost RMB financing through various financing channels to offset interest rate risks. In respect of renovation projects, the Manager will carry out the phased renovations of Four Seasons Hotel Guangzhou in an orderly manner to support the long-term preservation and appreciation of property value.About Yuexiu Real Estate Investment TrustYuexiu Real Estate Investment Trust ("Yuexiu REIT") was listed on the Hong Kong Stock Exchange of Hong Kong Limited on 21 December 2005 and is the first listed real estate investment trust only investing in properties in the People's Republic of China (the "PRC") in the world. As of 31 December 2025, Yuexiu REIT’s portfolio of properties consisted of ten properties (including one Qualified Minority-owned Property), namely, White Horse Building, Fortune Plaza, City Development Plaza, Victory Plaza, Guangzhou International Finance Centre (“GZIFC”), Yuexiu Financial Tower (a Qualified Minority-owned Property with a 49.495% beneficial interest) located in Guangzhou; Yue Xiu Tower located in Shanghai; Wuhan Yuexiu Fortune Centre, and Starry Victoria Shopping Centre located in Wuhan; Victory Business Centre located in Hangzhou; and Yue Xiu Building located in Hong Kong. The total gross floor area of the properties (excluding Yuexiu Financial Tower) was approximately 974,000 sq.m. All properties are located in the central business district of Guangzhou, Shanghai, Wuhan, Hangzhou and Hong Kong respectively. The categories of the properties include Grade-A offices, commercial complexes, retail business, hotel, serviced apartments and professional clothing market etc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月11日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀（01952.HK）宣佈，旗下自身免疫性疾病領域核心產品維適平(R)（精氨酸艾曲莫德片，VELSIPITY(R)）中國大陸首張處方在3月9日於中山大學附屬第一醫院開出，標志著這款創新療法正式進入中國臨床應用階段。據悉，在中國大陸首方開具當天，維適平(R)已在廣州、上海、杭州、西安、重慶、北京和南京7個核心城市的8家三甲醫院同步開出處方，實現上市首日即覆蓋全國重點區域患者，並通過互聯網醫院渠道進一步擴大患者覆蓋範圍。目前，該藥物已在中山大學附屬第一醫院、浙江大學醫學院附屬邵逸夫醫院、中國人民解放軍空軍軍醫大學第一附屬醫院、重慶市人民醫院、中國醫學科學院北京協和醫院等多家核心醫療機構惠及患者。值得關注的是，維適平(R)於今年2月獲得國家藥監局批准上市，僅一個月便實現中國大陸首方落地，推進速度明顯快於行業平均水平。業內認為，這不僅反映出該產品較高的臨床需求，也體現了雲頂新耀在創新藥商業化方面的執行效率。從疾病負擔來看，炎症性腸病（IBD）已被認為是全球增長最快的消化系統疾病之一。IBD主要包括潰瘍性結腸炎（UC）和克羅恩病（CD）。近年來，隨著飲食結構變化、生活方式改變以及診斷水平提升，中國患者數量持續增加。多家行業研究機構預計，到2030年前後，中國IBD治療市場規模有望突破百億元人民幣，其中新型小分子創新藥將成為主要增長動力之一。從臨床需求來看，潰瘍性結腸炎是一種病因尚不明確、易複發的慢性腸道炎症性疾病，臨床表現為黏液血便、腹痛、腹瀉、裏急後重等症狀，嚴重影響患者長期生活質量。近年來，中國該病發病率和患病率持續上升且呈年輕化趨勢，預計患者人數將由2025年的約98萬增長至2031年的約150萬。目前該病仍無法治愈，患者需長期用藥維持疾病控制，而傳統療法療效有限、生物制劑存在「療效天花板」，臨床亟需能實現更穩定、持久疾病控制的創新方案。維適平(R)作為每日口服一次的新一代高選擇性S1P受體調節劑，具備最佳藥物（best-in-disease）潛質，已獲得美國胃腸病學協會（AGA）臨床實踐指南與美國胃腸病學會（ACG）臨床指南強烈推薦，作為中重度潰瘍性結腸炎的一線用藥。多項全球臨床研究證實其療效與安全性良好，尤其在快速起效、實現無激素緩解及深度黏膜愈合方面具有明顯臨床優勢。在迄今最大規模的中重度UC患者亞洲多中心III期臨床研究（ENLIGHT UC）中，維適平(R)維持治療40周，臨床緩解率達48.1%，深度黏膜愈合率達51.9%，內鏡正常化率達45.5%。數據顯示，維適平(R)可實現強效深度黏膜愈合，從而改善疾病長期預後，並有助於降低複發及癌變風險。全球Ⅲ期ELEVATE研究的一項開放標簽擴展研究數據證實，持續維適平(R)治療3年，在觀察病例中，86.8%患者實現臨床應答，臨床緩解率和黏膜愈合率均維持在約60%水平。全球臨床研究隨訪5年的數據進一步表明其穩定且良好的安全性特征，整體耐受性良好。中華醫學會消化病學分會前任主任委員、中山大學附屬第一醫院消化內科學術帶頭人陳旻湖教授指出，維適平(R)此次首張處方的開具，有望進一步優化潰瘍性結腸炎的臨床管理路徑，推動疾病治療向更高水平發展，實現黏膜愈合的治療目標，惠及更多患者。雲頂新耀首席執行官羅永慶表示，黏膜愈合是當前潰瘍性結腸炎的治療目標，盡早實現可大幅降低患者疾病複發率、住院率、手術率和癌變風險。維適平(R)可從源頭控制腸道炎症，促進黏膜愈合，填補了中重度潰瘍性結腸炎治療領域的空白。作為一款治療潰瘍性結腸炎的創新一線治療藥物，維適平(R)兼具「療效、安全性及方便性」三重優勢，為患者提供長期疾病控制與生活質量改善的保障。此外，該藥物於2024年和2025年被納入粵港澳大灣區內地9市臨床急需進口港澳藥品醫療器械目錄，在大灣區率先實現臨床應用，且在真實診療場景中的表現與臨床研究療效、安全性一致。商業化層面，雲頂新耀已通過腎科核心產品耐賦康(R)驗證了成熟可複制的商業化能力。作為全球首個且目前唯一在中、美、歐獲得完全批准的IgA腎病對因治療藥物，耐賦康(R)在2025年前三季度銷售額突破10億元，創造了非腫瘤產品的曆史，成為過去十年慢病藥進醫保銷售最好的產品。該產品的成功，驗證了以「科學及商業洞察驅動的准入、醫學、市場、銷售一體化協同（A2MS）」為核心的創新藥商業化運營平台，也為後續產品的市場拓展提供了可複用的體系與經驗。此次維適平(R)首方快速落地，進一步印證了該平台的高效性，依托耐賦康(R)的渠道網絡與市場准入經驗，其有望複刻增長路徑。從市場格局來看，長期以來中國潰瘍性結腸炎治療市場以傳統免疫抑制劑和注射型生物制劑為主，這些方案存在口服便利性不足、長期安全性風險等問題。維適平(R)憑借差異化優勢，被業界認為有望填補這一需求缺口，行業普遍預期其銷售峰值可達50億元，成為驅動雲頂新耀業績增長的重要引擎。雲頂新耀表示，將構建多渠道准入體系，提供多元化患者援助項目和創新支付方案，並全力推動維適平(R)納入國家醫保目錄，以提升藥物的可及性和可負擔性。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com